CLDF Title
Home | Contact Us | Bookmark
HEPATITIS
HBV HCV HDV
CIRRHOSIS
CIRRHOSIS HEPATIC ENCEPHALOPATHY (HE) HEPATORENAL SYNDROME (HRS) THROMBOCYTOPENIA
NASH
CHOLESTATIC
PRIMARY BILIARY CHOLANGITIS (PBC)
HCC ALCOHOL LIVER DISEASE PEDIATRIC LIVER DISEASE
About CLDF
Board of Trustees Board of Advisors/Faculty CLDF Committees 2022 GI Fellow Board of Advisors
Embassy of Education  
Live Events Slide Library Webcasts Abstract Library Committee Members
 
HCV-Single Disease Content  
Featured Article

Live CME Meetings

Triple E for HCV: Treatment Expansion in High-Risk Communities: Engagement, Education and Eradication of HCV

This activity was developed for primary care physicians and health care professionals in the primary care field who manage patients with HCV and wish to improve standard practice care.
Recorded Educational Webinar

Webcasts
     
HBV, HCV, and HDV   Educational Webcast
Hepatitis C: Screening, Barriers and Access to Therapy   CME Audiocast
Management Challenges in HCV   CME Audiocast
The Role of Non-Invasive Biomarkers in Managing Patients with HCV   Educational Webinar
CME eNewsletter
     
  Newsletter  
     
  Credit Designation  
  1.0 AMA PRA  
  Category 1 Credit(s)™  
  Download  
     
  ACHS  
  Jointly sponsored by The Annenberg Center for Health Sciences at Eisenhower and the
Chronic Liver Disease Foundation.

This educational material was supported by an educational grant from AbbVie and Gilead. 		 
     
 
 
Triple E for HCV: Engagement, Education, and Eradication of HCV Among Patients with Substance Use Disorders
 
Target Audience
This activity is targeted to physicians and other health care providers who specialize in the management of patients with addictive disorders.
 
Educational Objectives
Upon completion of this activity, participants should be better able to:
• Recognize the risks of exposure to HCV in injection drug users and identify epidemiologic trends of HCV infection in this population
• Describe the natural history of chronic HCV infection
• Demonstrate how proper HCV screening and diagnosis, as well as implementation of antiviral therapy, can improve long term outcomes in injection drug users
 
Accreditation Statement
Please see page 1 of the newsletter for full accreditation statement.
 
 
 
Dynamic CME Resource Library
     
The HCV Treatment Revolution Continues: Resistance Considerations, Pangenotypic Efficacy, and Advances in Challenging Populations   CME eNewsletter
Management of Hep C/HIV Infection   Educational eNewsletter
Slide Library
   Released: 2021
Webcast
Triple E for HCV: Engagement, Education and Eradication - ASAM
68 slides
 
 
   Released: 2020
Webcast
Triple E for HCV: Engagement, Education, and Eradication
70 slides
 
 
   Released: 2020
test
Hepatitis C: Screening, Barriers and Access to Therapy
28 slides
 
 
   Released: 2019
Webcast
AATOD Conference
159 slides
 
 
   Released: 2019
Webcast
Triple E for HCV Satellite Symposium - NCCHC
81 slides
 
 
   Released: 2019
Webcast
Hot Topics in Cirrhosis
120 slides
 
 
   Released: 2019
Webcast
Triple E for HCV Satellite Symposium - ASAM
75 slides
 
 
   Released: 2019
Webcast
Hepatology News Tonight Managing Complications of Cirrhosis
129 slides
 
 
   Released: 2018
test
HCV Advances 2018
51 slides
 
 
   Released: 2018
test
Hepatology News Tonight: Managing Complication of Cirrhosis
57 slides
 
 
   Released: 2018
Webcast
Hepatitis Elimination Symposium and Workshop
96 slides
 
 
   Released: 2017
Webcast
HCV Advances 2017
54 slides
 
 
   Released: 2017
Webcast
Expert Perspectives: Highlights on HCV from EASL 2017
61 slides
 
 
   Released: 2016
Webcast
Expert Perspectives: Best of HCV - 2016 Spring Update
82 slides
 
 
     
 
 
Abstract Library
1.Hepatitis C virus monitoring in inpatient psychiatry: Doctors' practice
 

Australas Psychiatry. 2022 Oct 14;10398562221133277. doi: 10.1177/10398562221133277.Online ahead of print.

Matthew Cubin 1, Georgina M Luscombe 2, Gulnara Mammadova 3, Katherine Smith 4, Catherine Hickie 3
 
2.Milestones in the discovery of hepatitis C
 

World J Gastroenterol. 2022 Oct 7;28(37):5395-5402.doi: 10.3748/wjg.v28.i37.5395.

Octavio Campollo 1, Gerardo Amaya 2, P Aiden McCormick 3
 
3.Hepatitis C Virus-Specific Immune Responses Following Direct Acting Antivirals Administered During Recent Hepatitis C Virus Infection
 

J Viral Hepat. 2022 Oct 27. doi: 10.1111/jvh.13761. Online ahead of print.

Julia L Casey 1 2, Gregory J Dore 3, Jason Grebely 3, Gail V Matthews 3, Vera Cherepanov 1, Marianne Martinello 3, Philippa Marks 3, Harry L A Janssen 1, Bettina E Hansen 1 4, Rupert Kaul 5 6, Sonya A MacParland 7 8, Adam J Gehring 1 5, Jordan J Feld 1 2
 
4.Chronic hepatitis C infection is associated with higher incidence of extrahepatic cancers in a Canadian population based cohort
 

Front Oncol. 2022 Oct 13;12:983238. doi: 10.3389/fonc.2022.983238. eCollection 2022.

Maryam Darvishian 1 2, Terry Tang 1, Stanley Wong 3, Mawuena Binka 3 4, Amanda Yu 3, Maria Alvarez 3, Héctor Alexander Velásquez García 3, Prince Asumadu Adu 3 4, Dahn Jeong 3 4, Sofia Bartlett 3, Mohammad Karamouzian 3 5 6, Jean Damascene Makuza 3 4, Jason Wong 3, Alnoor Ramji 4, Ryan Woods 1 7, Mel Krajden 3 4, Naveed Janjua 3 4, Parveen Bhatti 1 2
 
5.Rapid detection of hepatitis C virus using recombinase polymerase amplification
 

PLoS One. 2022 Oct 25;17(10):e0276582. doi: 10.1371/journal.pone.0276582. eCollection 2022.

Catherine T Chia 1, Andrew T Bender 2, Lorraine Lillis 3, Benjamin P Sullivan 2, Coleman D Martin 4, Wynn Burke 5 6, Charles Landis 5, David S Boyle 3, Jonathan D Posner 2 4 7
 
6.Economic Impact of Universal Hepatitis C Virus Testing for Middle-Aged Adults Who Inject Drugs
 

Am J Prev Med. 2022 Oct 15;S0749-3797(22)00448-2. doi: 10.1016/j.amepre.2022.08.016.Online ahead of print.

Xinyi Jiang 1, Vakaramoko Diaby 2, Scott Martin Vouri 2, Weihsuan Lo-Ciganic 2, Robert L Parker 3, Wei Wang 1, Shao-Hsuan Chang 1, Debbie L Wilson 1, Linda Henry 1, Haesuk Park 4
 
7.Interventions to prevent HIV and Hepatitis C among people who inject drugs: Latest evidence of effectiveness from a systematic review (2011 to 2020)
 

Int J Drug Policy. 2022 Nov;109:103872. doi: 10.1016/j.drugpo.2022.103872.Epub 2022 Oct 3.

Norah Palmateer 1, Victoria Hamill 2, Anne Bergenstrom 3, Harriet Bloomfield 4, Lara Gordon 5, Jack Stone 5, Hannah Fraser 5, Thomas Seyler 3, Yuejiao Duan 4, Richard Tran 4, Kirsten Trayner 2, Christopher Biggam 2, Shanley Smith 2, Peter Vickerman 5, Matt Hickman 5, Sharon Hutchinson 2
 
8.Complicating cure: How Australian criminal law shapes imagined post-hepatitis C futures
 

Sociol Health Illn. 2022 Oct 18. doi: 10.1111/1467-9566.13562. Online ahead of print.

Kate Seear 1, Sean Mulcahy 1, Dion Kagan 1, Emily Lenton 1, Suzanne Fraser 1, Kylie Valentine 2, Adrian Farrugia 1
 
9.Hepatitis C Virus Infections in Patients with Hemophilia: Links, Risks and Management
 

J Multidiscip Healthc. 2022 Oct 10;15:2301-2309. doi: 10.2147/JMDH.S363177.eCollection 2022.

Anastasia Spanoudaki # 1, Nikolaos Papadopoulos # 2, Eleni-Myrto Trifylli 2, Evangelos Koustas 2, Sofia Vasileiadi 1, Melanie Deutsch 1
 
10.Finding Cases of Hepatitis C for Treatment Using Automated Screening in the Emergency Department is Effective, but What Is the Cost?
 

Can J Gastroenterol Hepatol. 2022 Oct 14;2022:3449938. doi: 10.1155/2022/3449938.eCollection 2022.

David Stephen Prince 1 2 3, Julia Di Girolamo 1 2, Joseph Louis Pipicella 1 2, Melissa Bagatella 1, Tahrima Kayes 1 2, Frank Alvaro 1 4, Michael Maley 1 3 4, Hong Foo 1 4 5, Paul MacConachie Middleton 1 2 3 6 7, Miriam Tania Levy 1 2 3
 
11.Treatment for hepatitis C virus with direct acting antiviral agents: Perspectives and treatment experiences of people who inject drugs
 

J Subst Abuse Treat. 2022 Sep;140:108768. doi: 10.1016/j.jsat.2022.108768. Epub 2022 Mar 18.

Alison Karasz 1, Reena Singh 2, M Diane McKee 3, Krupa Merchant 4, Arthur Y Kim 5, Kimberly Page 6, Irene Pericot-Valverde 7, Ellen S Stein 8, Lynn E Taylor 9, Katherine Wagner 10, Alain H Litwin 11
 
12.Impact of COVID-19 lockdown restrictions on hepatitis C testing in Australian primary care services providing care for people who inject drugs
 

J Viral Hepat. 2022 Oct;29(10):908-918. doi: 10.1111/jvh.13723. Epub 2022 Jul 5.

Michael W Traeger 1 2, Daniela K van Santen 1 2 3, Rachel Sacks-Davis 1 2, Jason Asselin 1, Allison Carter 4 5 6, Joseph S Doyle 1 7, Alisa Pedrana 1 2, Anna L Wilkinson 1 2, Jessica Howell 1 8 9, Rebecca Thatcher 10, John Didlick 11, Basil Donovan 4 12, Rebecca Guy 4, Margaret E Hellard 1 7 13, Mark A Stoové 1 2, Australia Collaboration for Coordinated Enhanced Sentinel Surveillance of Sexually Transmissible Infections and Blood Borne Viruses (ACCESS)
 
13.Impact of the COVID-19 pandemic on hepatitis B and C elimination: An EASL survey
 

JHEP Rep. 2022 Sep;4(9):100531. doi: 10.1016/j.jhepr.2022.100531. Epub 2022 Jul 27.

Loreta A Kondili 1, Maria Buti 2 3, Mar Riveiro-Barciela 2 3, Mojca Maticic 4 5, Francesco Negro 6, Thomas Berg 7, Antonio Craxì 8
 
14.Non-targeted hepatitis C virus screening in acute care healthcare settings in the Southern Appalachian region
 

J Am Coll Emerg Physicians Open. 2022 Sep 12;3(5):e12819. doi: 10.1002/emp2.12819.eCollection 2022 Oct.

Cody A Chastain 1, Cathy A Jenkins 2, Michelle Rose 3, Daniel Moore 4, Diana Parker 5, Barbra Cave 6, Jane Crowe 7, Sarah Adams 7, Marrieth G Rubio 8, Rachel Potter 9, Kimberly Quedado 10, Ian D Jones 11, Jin H Han 12, Wesley H Self 13
 
15.Dispensing of HIV and Hepatitis C Antivirals During COVID-19: An Interrupted Time-Series Analysis of U.S. National Data
 

Am J Prev Med. 2022 Oct;63(4):532-542. doi: 10.1016/j.amepre.2022.04.024.Epub 2022 May 20.

Timothy W Levengood 1, Andrew I Aronsohn 2, Kao-Ping Chua 3, Rena M Conti 4
 
16.The Hepatitis C Care Cascade During the Direct-Acting Antiviral Era in a United States Commercially Insured Population
 

Open Forum Infect Dis. 2022 Sep 2;9(9):ofac445. doi: 10.1093/ofid/ofac445.eCollection 2022 Sep.

Nicole D Ferrante 1 2, Craig W Newcomb 2, Kimberly A Forde 3, Charles E Leonard 2 4, Jessie Torgersen 2 5, Benjamin P Linas 6, Sarah E Rowan 7, David L Wyles 7, Jay Kostman 8, Stacey B Trooskin 5 8, Vincent Lo Re 3rd 2 5
 
17.What barriers delay treatment in patients with hepatitis C?
 

J Fam Pract. 2022 Sep;71(7):E22-E24. doi: 10.12788/jfp.0471.

Kimberly Crosby 1, Simone Bigelow 1, Viviane Sachs 1, Jennifer Weakley 1, Helga Skaftason 1, Toni Hoberecht 2
 
18.Changes in alcohol use during hepatitis C treatment in persons who inject drugs
 

J Viral Hepat. 2022 Nov;29(11):1004-1014.doi: 10.1111/jvh.13737. Epub 2022 Sep 2.

Madhuri Martin 1, Prerana J Roth 1 2 3, Jiajing Niu 4, Irene Pericot-Valverde 3 5, Moonseong Heo 5, Akhila Padi 1, Brianna L Norton 6, Matthew J Akiyama 6, Alain H Litwin 1 2 3
 
19.HCV hotline facilitates Hepatitis C elimination during the COVID-19 pandemic
 

J Viral Hepat. 2022 Sep 5. doi: 10.1111/jvh.13746. Online ahead of print.

Lukas Hartl 1 2, Mathias Jachs 1 2, David Bauer 1 2, Benedikt Simbrunner 1 2, David Chromy 1 2 3, Teresa Binter 1 2, Lisa Steininger 1 2, Caroline Schwarz 2 4, Michael Schwarz 2 4, Lukas Burghart 2 4, Robert Strassl 5, Michael Trauner 1, Michael Gschwantler 4, Mattias Mandorfer 1 2, Thomas Reiberger 1 2
 
20. Risk Factors for Incident Hypertension Within 1 Year of Initiating Antiretroviral Therapy Among People with HIV
 

AIDS Res Hum Retroviruses. 2022 Sep;38(9):735-742.doi: 10.1089/AID.2021.0213. Epub 2022 Aug 23.

Mohammed Siddiqui 1, T J Moore 2, Dustin M Long 3, Greer A Burkholder 1, Amanda Willig 1, Christina Wyatt 4, Sonya Heath 1, Paul Muntner 5, Edgar Turner Overton 1
 
21.Hepatitis C active viremia over time in an ED-based testing programme: Impact, disparities and surveillance tool
 

J Viral Hepat. 2022 Sep 5. doi: 10.1111/jvh.13744. Online ahead of print.

Lindy Reynolds 1, Ricardo Franco 2, Myles Prados 2, Joel B Rodgers 3, Delissa T Hand 4, Lauren A Walter
 
22.Direct-acting antiviral retreatment patterns for hepatitis C
 

J Manag Care Spec Pharm. 2022 Oct;28(10):1100-1110.doi: 10.18553/jmcp.2022.28.10.1100.

Shaquib Al Hasan 1, Daniel G Dauner 1, Abhijeet Rajpurohit 2, Joel F Farley 2
 
23.Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies
 

Clin Microbiol Infect. 2022 Oct;28(10):1321-1327. doi: 10.1016/j.cmi.2022.02.042.Epub 2022 Mar 10.

Khalis Mustafayev 1, Harrys Torres 2
 
24.Improving hepatitis C screening and access to treatment
 

JAAPA. 2022 Oct 1;35(10):17-21. doi: 10.1097/01.JAA.0000873784.48761.b2.

Ryan Alberts 1, AnnMarie Zimmermann, Anthony Martinez
 
25.Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies
 

Clin Microbiol Infect. 2022 Oct;28(10):1321-1327. doi: 10.1016/j.cmi.2022.02.042.Epub 2022 Mar 10.

Khalis Mustafayev 1, Harrys Torres 2
 
26.Improving hepatitis C screening and access to treatment
 

JAAPA. 2022 Oct 1;35(10):17-21. doi: 10.1097/01.JAA.0000873784.48761.b2.

Ryan Alberts 1, AnnMarie Zimmermann, Anthony Martinez
 
27.Direct-acting antiviral retreatment patterns for hepatitis C
 

J Manag Care Spec Pharm. 2022 Oct;28(10):1100-1110.doi: 10.18553/jmcp.2022.28.10.1100.

Shaquib Al Hasan 1, Daniel G Dauner 1, Abhijeet Rajpurohit 2, Joel F Farley 2
 
28.Hepatitis C active viremia over time in an ED-based testing programme: Impact, disparities and surveillance tool
 

J Viral Hepat. 2022 Sep 5. doi: 10.1111/jvh.13744. Online ahead of print.

Lindy Reynolds 1, Ricardo Franco 2, Myles Prados 2, Joel B Rodgers 3, Delissa T Hand 4, Lauren A Walter 1
 
29.Risk Factors for Incident Hypertension Within 1 Year of Initiating Antiretroviral Therapy Among People with HIV
 

AIDS Res Hum Retroviruses. 2022 Sep;38(9):735-742.doi: 10.1089/AID.2021.0213. Epub 2022 Aug 23.

Mohammed Siddiqui 1, T J Moore 2, Dustin M Long 3, Greer A Burkholder 1, Amanda Willig 1, Christina Wyatt 4, Sonya Heath 1, Paul Muntner 5, Edgar Turner Overton 1
 
30.High Satisfaction with Patient-Centered Telemedicine for Hepatitis C Virus Delivered to Substance Users: A Mixed-Methods Study
 

Telemed J E Health. 2022 Aug 4. doi: 10.1089/tmj.2022.0189. Online ahead of print.

Andrew H Talal 1, Elisavet M Sofikitou 2, Kejia Wang 2, Suzanne Dickerson 3, Urmo Jaanimägi 1, Marianthi Markatou 2
 
31.Internet-guided HCV-RNA testing: A promising tool to achieve hepatitis C micro-elimination among men who have sex with men
 

J Viral Hepat. 2022 Aug;29(8):677-684. doi: 10.1111/jvh.13706. Epub 2022 May 28.

Tamara Prinsenberg 1 2, Janke Schinkel 1 3, Paul Zantkuijl 4, Udi Davidovich 2 5, Maria Prins 1 2, Marc van der Valk 1 6
 
32.Evaluating the Impact of an Educational Intervention on Hepatitis C Screening in a Midwest Regional Psychiatric Unit
 

J Am Psychiatr Nurses Assoc. 2022 Aug 5;10783903221115741.doi: 10.1177/10783903221115741. Online ahead of print.

Amy D Northrup 1, Courtney R Gignac 2, Hiba Wehbe-Alamah 3, Denise Cooper 4
 
33."You need a designated officer" - Recommendations from correctional and justice health personnel for scaling up hepatitis C treatment-as-prevention in the prison setting
 

Int J Drug Policy. 2022 Aug;106:103746. doi: 10.1016/j.drugpo.2022.103746. Epub 2022 May 27.

L Lafferty 1, J Rance 2, M Byrne 3, A Milat 4, G J Dore 5, J Grebely 5, A R Lloyd 5, C Treloar 2, SToP-C Study Group
 
34.Impact of an Accelerated Pretreatment Evaluation on Linkage-to-Care for Hepatitis C-infected Persons Who Inject Drugs
 

Subst Abuse. 2022 Aug 12;16:11782218221119068. doi: 10.1177/11782218221119068.eCollection 2022.

Valérie Martel-Laferrière 1 2 3, Suzanne Brissette 1 2 3, Claire Wartelle-Bladou 1 2 3, Louis-Christophe Juteau 1 2 3, Maria Popa 1, Marie-Ève Goyer 1 4, Julie Bruneau 1 2 3
 
35.Randomized clinical trial: Direct-acting antivirals as treatment for hepatitis C in people who inject drugs: Delivered in needle and syringe programs via directly observed therapy versus fortnightly collection
 

J Viral Hepat. 2022 Aug;29(8):646-653. doi: 10.1111/jvh.13701.Epub 2022 May 26.

Lewis Beer 1, Sarah Inglis 1, Amy Malaguti 2, Christopher Byrne 1 3, Christian Sharkey 4, Emma Robinson 3 4, Kirsty Gillings 5, Andrew Radley 6, Adrian Hapca 1, Brian Stephens 4, John Dillon 3 4
 
36.Comparing timelines and evidence available to support new TB, HIV, and HCV drug approvals: The same, only different
 

PLoS One. 2022 Jul 25;17(7):e0271102.doi: 10.1371/journal.pone.0271102. eCollection 2022.

Allison LaHood 1, Rifat Rahman 2, Lindsay McKenna 3, Mike Frick 3, Carole D Mitnick 1
 
37.Barriers to accessing sterile injecting equipment for people who inject drugs: An integrative review
 

J Clin Nurs. 2022 Sep 6. doi: 10.1111/jocn.16517. Online ahead of print.

Elaine Lawson 1, Helen Walthall 1 2
 
38.Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort Study
 

Ann Intern Med. 2022 Sep;175(9):1221-1229. doi: 10.7326/M21-4119. Epub 2022 Aug 9.

Jason Grebely 1, Gregory J Dore 1, Frederick L Altice 2, Brian Conway 3, Alain H Litwin 4, Brianna L Norton 4, Olav Dalgard 5, Edward J Gane 6, Oren Shibolet 7, Ronald Nahass 8, Anne F Luetkemeyer 9, Cheng-Yuan Peng 10, David Iser 11, Isaias Noel Gendrano 12, Michelle M Kelly 12, Peggy Hwang 12, Ernest Asante-Appiah 12, Barbara A Haber 12, Eliav Barr 12, Michael N Robertson 12, Heather Platt 12
 
39.Sustainable and equivalent improvements in symptoms and functional well-being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial
 

J Viral Hepat. 2022 Sep;29(9):795-806. doi: 10.1111/jvh.13716.Epub 2022 Jun 15.

Donna M Evon 1, Meichen Dong 2, Bryce B Reeve 3, Joy Peter 4, Larry Michael 5, Anna S Lok 6, David R Nelson 4, Paul W Stewart 2
 
40.Vital Signs: Hepatitis C Treatment Among Insured Adults - United States, 2019-2020
 

MMWR Morb Mortal Wkly Rep. 2022 Aug 12;71(32):1011-1017. doi: 10.15585/mmwr.mm7132e1.

William W Thompson, Hasan Symum, Amy Sandul, DHSc; Neil Gupta, Priti Patel, Noele Nelson, Jonathan Mermin, Carolyn Wester
 
41.Transformation of identity in substance use as a pathway to recovery and the potential of treatment for hepatitis C: a systematic review
 

Addiction. 2022 Aug 22. doi: 10.1111/add.16031. Online ahead of print.

Sarah R Donaldson 1 2, Andrew Radley 1 2, John F Dillon 1 3
 
42.Hepatitis C virus infection preceding an outbreak of HIV among persons who inject drugs- Kanawha County, West Virginia, 2019-2021
 

Clin Infect Dis. 2022 Jul 29;ciac619. doi: 10.1093/cid/ciac619. Online ahead of print.

Alana G Hudson 1, Robert A Bonacci 2 3, Anne C Moorman 4, McKenna Penley 5 6, Suzanne M Wilson 1, Jessica L Hoffman 1, Erica R Thomasson 7 8, R Paul McClung 3, Danae Bixler 4
 
43.One-year immunologic outcomes of lung transplantation utilizing hepatitis C-viremic donors
 

Clin Transplant. 2022 Aug;36(8):e14749. doi: 10.1111/ctr.14749. Epub 2022 Jun 17.

Tyler C Lewis 1, Melissa Lesko 1, Darya Rudym 1, Bonnie E Lonze 1, Massimo Mangiola 1, Jake G Natalini 1, Justin C Y Chan 2, Stephanie H Chang 2, Luis F Angel 1
 
44.Care Navigation Increases Initiation of Hepatitis C Treatment After Release From Prison in a Prospective Randomized Controlled Trial: The C-LINK Study
 

Open Forum Infect Dis. 2022 Jul 28;9(8):ofac350. doi: 10.1093/ofid/ofac350.eCollection 2022 Aug.

Timothy Papaluca 1, Anne Craigie 1, Lucy McDonald 1, Amy Edwards 1, Rebecca Winter 1, Annabelle Hoang 1, Alex Pappas 1, Aoife Waldron 1, Kelsey McCoy 1, Mark Stoove 2, Joseph Doyle 2, Margaret Hellard 2, Jacinta Holmes 1, Michael MacIsaac 1, Paul Desmond 1, David Iser 1, Alexander J Thompson 1
 
45.Hepatitis C virus risk among young people who inject drugs
 

Front Public Health. 2022 Jul 29;10:835836. doi: 10.3389/fpubh.2022.835836.eCollection 2022.

Pedro Mateu-Gelabert 1, Nasim S Sabounchi 2, Honoria Guarino 1, Courtney Ciervo 1, Kellie Joseph 1, Benjamin J Eckhardt 3, Chunki Fong 1, Shashi N Kapadia 4, Terry T K Huang 2
 
46.Hepatitis B and C in Children
 

Clin Liver Dis. 2022 Aug;26(3):403-420. doi: 10.1016/j.cld.2022.03.005.Epub 2022 Jun 25.

A Bailey Sperry 1, Aaron Bennett 2, Jessica Wen 3
 
47.Meta-analysis: diagnostic accuracy of hepatitis C core antigen detection during therapy with direct-acting antivirals
 

Aliment Pharmacol Ther. 2022 Aug 28. doi: 10.1111/apt.17198. Online ahead of print.

Daniel Sepúlveda-Crespo 1, Ana Treviño-Nakoura 2, José M Bellon 3, Beatriz Ardizone Jiménez 1, María A Jiménez-Sousa 1 4, Amanda Fernández-Rodríguez 1 4, Isidoro Martínez 1 4, Salvador Resino 1 4
 
48.Drug-drug interactions between antithrombotics and direct-acting antivirals in hepatitis C virus (HCV) patients: A brief, updated report
 

Front Pharmacol. 2022 Aug 9;13:916361. doi: 10.3389/fphar.2022.916361.eCollection 2022.

Mario Enrico Canonico 1, Giuseppe Damiano Sanna 2, Roberta Siciliano 3, Fernando Scudiero 4, Giovanni Esposito 1, Guido Parodi 5 6
 
49.Substance Use Disorder Treatment Providers' Knowledge and Opinions Toward Testing and Treatment of Chronic Hepatitis C in Rural North Carolina
 

Rural Ment Health. 2022 Jul;46(3):162-173. doi: 10.1037/rmh0000200. Epub 2022 Feb 3.

Donna M Evon 1, Christopher B Hurt 2, Delesha M Carpenter 3, Sarah K Rhea 4, Caitlin M Hennessy 4, William A Zule 4
 
50.A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study
 

Viruses. 2022 Jul 16;14(7):1555. doi: 10.3390/v14071555.

Anna Conway 1 2, Heather Valerio 1, Maryam Alavi 1, David Silk 1, Carla Treloar 2, Behzad Hajarizadeh 1, Alison D Marshall 1 2, Marianne Martinello 1, Andrew Milat 3, Adrian Dunlop 4 5, Carolyn Murray 6, Bianca Prain 6, Charles Henderson 7, Janaki Amin 8, Phillip Read 9, Pip Marks 1, Louisa Degenhardt 10, Jeremy Hayllar 11, David Reid 12, Carla Gorton 13, Thao Lam 14, Michael Christmass 15 16, Alexandra Wade 17 18, Mark Montebello 19, Gregory J Dore 1, Jason Grebely 1, ETHOS Engage Study Group
 
51.LOXL-2 and TNC-C are markers of liver fibrogenesis in HCV/HIV-, HIV- and HCV-infected patients
 

Biomark Med. 2022 Aug;16(11):839-846. doi: 10.2217/bmm-2021-0596. Epub 2022 Jul 5.

Akif Altinbas 1, Jacinta A Holmes 1, Shadi Salloum 1, Anna Lidofsky 1, Nadia Alatrakchi 1, Ma Somsouk 2, Peter Hunt 2, Steven Deeks 2, Kara W Chew 3, Georg Lauer 1, Annie Kruger 1, Wenyu Lin 1, Raymond T Chung 1
 
52.Sofosbuvir in the Treatment of Hepatitis E virus Infection: A Review of in vitro and in vivo Evidence
 

J Clin Exp Hepatol. 2022 Jul-Aug;12(4):1225-1237. doi: 10.1016/j.jceh.2022.02.003.Epub 2022 Feb 22.

Temi Lampejo 1
 
53.Improving Access to High-Value, High-Cost Medicines: The Use of Subscription Models to Treat Hepatitis C using Direct Acting Antivirals in the United States
 

J Health Polit Policy Law. 2022 Jul 14;10041121. doi: 10.1215/03616878-10041121.Online ahead of print.

Samantha G Auty 1, Kevin N Griffith 2, Paul R Shafer 1, Rebekah E Gee 3, Rena M Conti 1
 
54.Rapid Treatment Initiation for Hepatitis C in Young People Who Inject Drugs: The Seek, Test, and Rapid Treatment Randomized Trial
 

Open Forum Infect Dis. 2022 May 7;9(7):ofac225. doi: 10.1093/ofid/ofac225.eCollection 2022 Jul.

Benjamin Eckhardt 1, Shashi N Kapadia 2, Pedro Mateu-Gelabert 3, Melinda Pai 2, Chunki Fong 3, Yesenia Aponte-Melendez 3, Kristen M Marks 2
 
55.VirA+EmiC project: Evaluating real-world effectiveness and sustainability of integrated routine opportunistic hepatitis B and C testing in a large urban emergency department
 

J Viral Hepat. 2022 Jul;29(7):559-568. doi: 10.1111/jvh.13676. Epub 2022 Apr 9.

Gaia Nebbia 1, Murad Ruf 2, Laura Hunter 3, Sooria Balasegaram 4, Terry Wong 5, Ranjababu Kulasegaram 6, Julian Surey 7 8, Zana Khan 9, Jack Williams 10, Basel Karo 11, Luke Snell 1, Barnaby Flower 12, Hannah Evans 4 13, Sam Douthwaite 1
 
56.Defer no more: advances in the treatment and prevention of chronic hepatitis C virus infection in children
 

Curr Opin Infect Dis. 2022 Jul 15. doi: 10.1097/QCO.0000000000000856. Online ahead of print.

Jonathan R Honegger 1 2 3, Charitha Gowda 1 2 4
 
57.Sex-Specific Risk Factors and Health Disparity Among Hepatitis C Positive Patients Receiving Pharmacotherapy for Opioid Use Disorder: Findings From a Propensity Matched Analysis
 

J Addict Med. 2022 Jul-Aug;16(4):e248-e256. doi: 10.1097/ADM.0000000000000937.Epub 2021 Nov 18.

Brittany B Dennis 1, Leslie J Martin, Leen Naji, Daud Akhtar, George Cholankeril, Donghee Kim, Nitika Sanger, Alannah Hillmer, Caroul Chawar, Alessia D'Elia, Balpreet Panesar, Andrew Worster, David C Marsh, Tim O'Shea, Monica Bawor, Lehana Thabane, Zainab Samaan, Aijaz Ahmed
 
58.Risk factors for hepatitis C virus infection at a large urban emergency department
 

J Viral Hepat. 2022 Jul 5. doi: 10.1111/jvh.13730. Online ahead of print.

James S Ford 1, Erika Hollywood 2, Bradley Steuble 3, Zichun Meng 4, Stephanie Voong 5, Tasleem Chechi 5, Nam Tran 6, Larissa May 5
 
59.Impact of Hepatitis C Treatment Uptake on Cirrhosis and Mortality in Persons Who Inject Drugs : A Longitudinal, Community-Based Cohort Study
 

Ann Intern Med. 2022 Jul 12. doi: 10.7326/M21-3846. Online ahead of print.

Javier A Cepeda 1, David L Thomas 2, Jacqueline Astemborski 1, Jacqueline E Rudolph 1, Rachel Gicquelais 3, Gregory D Kirk 2, Shruti H Mehta 1
 
60.Outcomes of a Pharmacist-Led Hepatitis C Virus Treatment Program in an Urban Safety-Net Health System, Chicago, 2017-2019
 

Public Health Rep. 2022 Jul-Aug;137(4):702-710. doi: 10.1177/00333549211015664.Epub 2021 May 27.

Bijou R Hunt 1, Hollyn Cetrone 2, Sharon Sam 1, Nancy R Glick 1 3
 
61.Low incidence and prevalence of hepatitis C in two cohorts of HIV pre-exposure prophylaxis adherence interventions in men who have sex with men in Southern California
 

J Viral Hepat. 2022 Jul;29(7):529-535. doi: 10.1111/jvh.13678. Epub 2022 Apr 12.

Adiba Hassan 1 2, Harold Glenn San Agustin 3, Leah Burke 1, Ryan Kofron 4, Katya Corado 5, Robert Bolan 6, Raphael J Landovitz 4, Michael P Dubé 3, Sheldon R Morris 1
 
62.Donors with human immunodeficiency virus and hepatitis C virus for solid organ transplantation: what's new
 

Curr Opin Infect Dis. 2022 Aug 1;35(4):321-329. doi: 10.1097/QCO.0000000000000840.Epub 2022 Jul 5.

Stephanie A Lushniak 1, Christine M Durand
 
63.An adaptable platform for in-house hepatitis C serology
 

J Virol Methods. 2022 Jul 16;308:114586. doi: 10.1016/j.jviromet.2022.114586.Online ahead of print.

Jannie Pedersen 1, Irène Pegha Moukandja 2, Stella Ndidi 2, Anna-Louise Sørensen 3, Ismaël Hervé Koumakpayi 2, Jean-Bernard Lekana-Douki 4, Marie-Louise Vachon 5, Nina Weis 3, Gary Kobinger 6, Hugues Fausther-Bovendo 7
 
64.Prevalence and incidence of hepatitis C infection amongst men who have sex with men in a population-based pre-exposure prophylaxis program in British Columbia, Canada
 

Liver Int. 2022 Jul;42(7):1528-1535. doi: 10.1111/liv.15237. Epub 2022 Mar 28.

Kyle A Thompson 1, Gabriel Blank 2, Junine Toy 1, David M Moore 1 2, Nathan Lachowsky 3, Nicanor Bacani 1, Wendy Zhang 1, Paul Sereda 1, Viviane D Lima 1 2, Rolando Barrios 1, Julio S G Montaner 1 2, Mark W Hull 1 2
 
65.Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R)
 

Viruses. 2022 Jul 14;14(7):1541. doi: 10.3390/v14071541.

Markus Cornberg 1, Albrecht Stoehr 2, Uwe Naumann 3, Gerlinde Teuber 4, Hartwig Klinker 5, Thomas Lutz 6, Hjördis Möller 7, Dennis Hidde 8, Kristina Lohmann 8, Karl-Georg Simon 9
 
66.Hepatitis C Elimination in the Netherlands (CELINE): How nationwide retrieval of lost to follow-up hepatitis C patients contributes to micro-elimination
 

Eur J Intern Med. 2022 Jul;101:93-97. doi: 10.1016/j.ejim.2022.04.024. Epub 2022 May 5.

Cas J Isfordink 1, Marleen van Dijk 2, Sylvia M Brakenhoff 3, Patricia A M Kracht 4, Joop E Arends 4, Robert J de Knegt 3, Marc van der Valk 5, Joost P H Drenth 6, CELINE Study Group
 
67.Real-world experience for the outcomes and costs of treating hepatitis C patients: Results from the German Hepatitis C-Registry (DHC-R)
 

Z Gastroenterol. 2022 Jul 15. doi: 10.1055/a-1852-5713. Online ahead of print.

Kathrin Krüger # 1, Siegbert Rossol # 2, Christian Krauth 1, Peter Buggisch 3, Stefan Mauss 4, Albrecht Stoehr 3, Hartwig Klinker 5, Klaus Böker 6, Gerlinde Teuber 7, Jona Stahmeyer 1
 
68.Systematic Review of Hepatitis C Virus Prevalence in the WHO Western Pacific Region
 

Viruses. 2022 Jul 15;14(7):1548. doi: 10.3390/v14071548.

Jenny Iversen 1, Handan Wand 1, Po-Lin Chan 2, Linh-Vi Le 2, Lisa Maher 1
 
69.Hepatitis C virus (HCV) seroprevalence, RNA detection, and genotype distribution across Florida, 2015-2018
 

Prev Med. 2022 Aug;161:107136. doi: 10.1016/j.ypmed.2022.107136. Epub 2022 Jul 5.

Brittney L Dickey 1, Anna E Coghill 1, Julie A Rathwell 1, Richard R Reich 2, Susan T Vadaparampil 3, Shannon M Christy 4, Richard Roetzheim 5, Elizabeth Shenkman 6, Anna R Giuliano 7
 
70.Hepatitis C and HIV Screening, Testing, and Risk Perceptions among South-Central Appalachian County Health Department Staff
 

South Med J. 2022 Jul;115(7):422-428. doi: 10.14423/SMJ.0000000000001409.

Chase Harless 1, Brunilda Lugo 1, Bayla Ostrach 1
 
71.Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication
 

J Hepatol. 2022 Jul;77(1):55-62. doi: 10.1016/j.jhep.2022.01.027. Epub 2022 Feb 12.

Peter P Mueller 1, Qiushi Chen 2, Turgay Ayer 3, Gizem S Nemutlu 1, Ali Hajjar 1, Emily D Bethea 4, Mary Linton B Peters 5, Brian P Lee 6, Naveed Z Janjua 7, Fasiha Kanwal 8, Jagpreet Chhatwal 9
 
72.Hepatitis C Virus Prevalence, Medical Status Awareness and Treatment Engagement among Homeless People Who use Drugs: Results of a Street Outreach Study
 

Subst Abuse. 2022 May 26;16:11782218221095871. doi: 10.1177/11782218221095871.eCollection 2022.

Rinat Lasmanovich 1, Or Shaked 1, Ayelet Sivan 1, Idan Barak 2, Mor Nahari 3, Orna Mor 4, Helena Katchman 5
 
73.Hepatitis C is associated with more adverse pregnancy outcomes than hepatitis B: A 7-year national inpatient sample study
 

Hepatol Commun. 2022 Jun 24. doi: 10.1002/hep4.2002. Online ahead of print.

Bing Chen 1, Yichen Wang 2, Marcia Lange 3, Tatyana Kushner 3 4
 
74.Trends in the use of hepatitis C viremic donor hearts
 

J Thorac Cardiovasc Surg. 2022 May;163(5):1873-1885.e7. doi: 10.1016/j.jtcvs.2020.09.044.Epub 2020 Sep 16.

Selena S Li 1, Asishana Osho 2, Philicia Moonsamy 2, David A D'Alessandro 2, Gregory D Lewis 3, Mauricio A Villavicencio 2, Thoralf M Sundt 3rd 2, Masaki Funamoto 4
 
75.Hepatitis C virus (HCV) micro-elimination in the hospital setting: The results of the HCV Caserta hospital project
 

J Infect Public Health. 2022 May;15(5):562-565. doi: 10.1016/j.jiph.2022.04.003.Epub 2022 Apr 12.

Vincenzo Messina 1, Mariantonietta Pisaturo 2, Loredana Alessio 2, Antonio Russo 2, Elena Tripaldelli 3, Arnolfo Petruzziello 3, Angela Annecchiarico 4, Maria Rosaria Romano 5, Paolo Maggi 6, Nicola Coppola 7
 
76.Hepatitis C antibody prevalence, correlates and barriers to care among people who inject drugs in Central California
 

J Viral Hepat. 2022 Jul;29(7):518-528. doi: 10.1111/jvh.13677. Epub 2022 Apr 6.

Jenny E Ozga 1, Jennifer L Syvertsen 2, Robin A Pollini 1 3 4
 
77.Patients with severe mental illness and hepatitis C virus infection benefit from new pangenotypic direct-acting antivirals: Results of a literature review
 

Gastroenterol Hepatol. 2022 Jun 17;S0210-5705(22)00164-9.doi: 10.1016/j.gastrohep.2022.06.001. Online ahead of print.

Luis Gutiérrez-Rojas 1, Jesús José de la Gándara Martín 2, Luisa García Buey 3, Juan I Uriz Otano 4, Álvaro Mena 5, Carlos Roncero 6
 
78.Medicaid Hepatitis C Virus Treatment Policies: Impact on Testing and Treatment in the Commercially Insured
 

Am J Prev Med. 2022 Jun 17;S0749-3797(22)00161-1. doi: 10.1016/j.amepre.2022.03.010.Online ahead of print.

Rachel L Epstein 1, Jianing Wang 2, Laura F White 2, Shashi N Kapadia 3, Jake R Morgan 4, Yuhua Bao 5, Benjamin P Linas 6
 
79.Hepatitis C coinfection and extrahepatic cancer incidence among people living with HIV
 

HIV Med. 2022 Jul;23(6):620-628. doi: 10.1111/hiv.13218. Epub 2021 Dec 23.

Sarah J Willis 1, H Nina Kim 2, Chad J Achenbach 3, Edward R Cachay 4, Katerina A Christopoulos 5, Heidi M Crane 2, Ricardo A Franco 6, Christopher B Hurt 7, Mari M Kitahata 2, Richard D Moore 8, Michael J Silverberg 9, Phyllis C Tien 5 10, Daniel Westreich 11, Julia L Marcus 1
 
80.Hepatitis C Elimination During a Global Pandemic: A Case Study of Resilience in Action
 

Public Health Rep. 2022 Jul-Aug;137(4):649-654. doi: 10.1177/00333549221083741.Epub 2022 Apr 9.

Shelley N Facente 1 2, Rachel Grinstein 3, Janessa Broussard 4, Jessica Shost 5, Soraya Azari 6 7, Jennifer Siruno 6 7, Jose A Jimenez 2, Anne F Luetkemeyer 6 8, Katie Burk 2 3
 
81.Future destinations and social inclusion scoping review: how people cured of hepatitis C (HCV) using direct- acting antiviral drugs progress in a new HCV-free world
 

Subst Abuse Treat Prev Policy. 2022 Jun 8;17(1):45.doi: 10.1186/s13011-022-00475-1.

Sarah R Donaldson 1 2, Andrew Radley 3 4, John F Dillon 3 4
 
82.Approaches and strategies to manage the hepatitis C virus-positive heart donor
 

Curr Opin Organ Transplant. 2022 Jun 1;27(3):229-234.doi: 10.1097/MOT.0000000000000984.

Brent C Lampert 1, Kevin Kissling 2
 
83.Breakthroughs in hepatitis C research: from discovery to cure
 

Nat Rev Gastroenterol Hepatol. 2022 May 20;1-18.doi: 10.1038/s41575-022-00608-8. Online ahead of print.

Michael P Manns 1, Benjamin Maasoumy 2
 
84.Direct-Acting Antiviral Agents for Hepatitis C Virus Infection-From Drug Discovery to Successful Implementation in Clinical Practice
 

Viruses. 2022 Jun 17;14(6):1325. doi: 10.3390/v14061325.

Christopher Dietz 1, Benjamin Maasoumy 1
 
85.Safety and efficacy of sofosbuvir-based medication regimens with and without ribavirin in hepatitis C patients: A systematic review and meta-analysis
 

J Clin Pharm Ther. 2022 Jun 8. doi: 10.1111/jcpt.13698. Online ahead of print.

Shaimaa Elshafie 1 2, Rupal Trivedi-Kapoor 1, Mark Ebell 3
 
86.Diagnostic Accuracy of Point-of-Care HCV Viral Load Assays for HCV Diagnosis: A Systematic Review and Meta-Analysis
 

Diagnostics (Basel). 2022 May 18;12(5):1255. doi: 10.3390/diagnostics12051255.

Weiming Tang 1 2, Yusha Tao 1 2, Emmanuel Fajardo 3, Elena Ivanova Reipold 4, Roger Chou 5, Joseph D Tucker 1 2, Philippa Easterbrook 3
 
87.Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression
 

Lancet HIV. 2022 Jun;9(6):e414-e427.doi: 10.1016/S2352-3018(22)00077-7.

Samira Hosseini-Hooshyar 1, Behzad Hajarizadeh 2, Sahar Bajis 2, Matthew Law 2, Naveed Z Janjua 3, Daniel S Fierer 4, David Chromy 5, Jürgen K Rockstroh 6, Thomas C S Martin 7, Patrick Ingiliz 8, Chien-Ching Hung 9, Gregory J Dore 2, Marianne Martinello 2, Gail V Matthews 2
 
88.Safety and Antiviral Activity of EGFR Inhibition by Erlotinib in Chronic Hepatitis C Patients: A Phase Ib Randomized Controlled Trial
 

Clin Transl Gastroenterol. 2022 Jun 1;13(6):e00492.doi: 10.14309/ctg.0000000000000492.

Antonio Saviano 1 2 3 4 5, François Habersetzer 1 2 3 4 5, Joachim Lupberger 1 2, Pauline Simo-Noumbissie 3, Catherine Schuster 1 2, Michel Doffoël 3, Catherine Schmidt-Mutter 4, Thomas F Baumert 5
 
89.Blood-borne virus testing in emergency departments - a systematic review of seroprevalence, feasibility, acceptability and linkage to care
 

HIV Med. 2022 Jun 14. doi: 10.1111/hiv.13328. Online ahead of print.

Ruth Simmons 1 2, James Plunkett 1, Lukasz Cieply 1, Samreen Ijaz 2 3, Monica Desai 1 2, Sema Mandal 1 2
 
90.Hepatitis C viral clearance with coadministration of crushed sofosbuvir/velpatasvir and high-dose pantoprazole after liver transplantation
 

Am J Health Syst Pharm. 2022 Jun 8;zxac153. doi: 10.1093/ajhp/zxac153. Online ahead of print.

Dawn M Pluckrose 1, Amanda Szczepanik 2, Sarah E Bova 2, Sari R Freedman 2
 
91.Hepatitis C prevalence and key population size estimate updates in San Francisco: 2015 to 2019
 

PLoS One. 2022 May 11;17(5):e0267902. doi: 10.1371/journal.pone.0267902. eCollection 2022.

Shelley N Facente 1 2, Rachel Grinstein 3, Roberta Bruhn 2, Zhanna Kaidarova 2, Erin Wilson 3, Jennifer Hecht 4 5, Katie Burk 1 3, Eduard Grebe 2 6 7, Meghan D Morris 6
 
92.A complex increase in hepatitis C virus in a correctional facility: bumps in the road
 

Aust N Z J Public Health. 2022 Jun;46(3):377-381. doi: 10.1111/1753-6405.13238.Epub 2022 Apr 18.\

Lea Merone 1, Sian Ashton 1 2, Andy Harris 3, Wanjibung Shaun Edwards 1, Annie Preston-Thomas 1, Richard Gair 1, Darren B Russell 2 4
 
93.Influence of hepatitis C viral parameters on pregnancy complications and risk of mother-to-child transmission
 

J Hepatol. 2022 May 25;S0168-8278(22)00331-2. doi: 10.1016/j.jhep.2022.05.016.Online ahead of print.

Tatyana Kushner 1, Maya Djerboua 2, Mia J Biondi 3, Jordan J Feld 4, Norah Terrault 5, Jennifer A Flemming 6
 
94.Risk of hepatocellular carcinoma in patients with chronic hepatitis c infection and stage 3 fibrosis after sustained virological response
 

Rev Esp Enferm Dig. 2022 Jun;114(6):309-311. doi: 10.17235/reed.2022.8840/2022.

Antonio Olveira Martín 1, María Luisa García Montes 2, María Sanchez-Azofra 3

 

 
 
95.Effect of Hepatitis C Viremia on Posttransplant Diabetes Mellitus in Liver Transplant Recipients
 

Prog Transplant. 2022 Mar;32(1):73-77. doi: 10.1177/15269248211064879. Epub 2021 Dec 7.

Kelsey Klein 1 1 2 3, Joelle Nelson 1 1 2 3, Christina Long 1 2 4, Kermit Speeg 1 5, Naim Alkhouri 6, Reed Hall 1 1 2 3
 
96.Hepatitis C virus infection and diabetes: A complex bidirectional relationship
 

Diabetes Res Clin Pract. 2022 May;187:109870. doi: 10.1016/j.diabres.2022.109870.Epub 2022 Apr 7.

Stefano Ciardullo 1, Alessandro Mantovani 2, Antonio Ciaccio 3, Marco Carbone 3, Pietro Invernizzi 3, Gianluca Perseghin 4
 
97.Hepatitis C mortality trends in San Francisco: can we reach elimination targets?
 

Ann Epidemiol. 2022 Jan;65:59-64. doi: 10.1016/j.annepidem.2021.10.004. Epub 2021 Oct 23.

Ali Mirzazadeh 1, Shelley N Facente 2, Katie Burk 3, James G Kahn 4, Meghan D Morris 5, End Hep C SF
 
98.Hepatitis C Virus Reflex Testing Protocol in an Emergency Department
 

West J Emerg Med. 2022 Feb 28;23(2):108-114. doi: 10.5811/westjem.2021.10.52468.

Jacob J Manteuffel 1, Madison S Lee 1, Rebecca M Bussa 1, Noor L Sabagha 1, Kaleem Chaudhry 1, Jacob E Ross 1, Megan R Cook 1, Jo-Ann K Rammal 1, Karthik Sridasyam 1, Howard A Klausner 1, Linoj P Samuel 2, Joseph B Miller 1
 
99.Hepatitis C eradication improves cognitive function in patients with or without cirrhosis: A prospective real-life study
 

Eur J Neurol. 2022 Feb;29(2):400-412. doi: 10.1111/ene.15138. Epub 2021 Nov 2.

Luis Ibáñez-Samaniego 1 2 3, Marta Rapado-Castro 4 5 6, Lucia Cabrero 2 3, Cristina Navarrete 1, Seila García-Mulas 1, Adriana Ahumada 1, Laura Marquez 1, Maria Dolores Pérez 1, Diego Rincon 1 2 3 6, Rafael Bañares 1 2 3 6, Rita Garcia-Martinez 2 3 6 7
 
100.Special Considerations in the Management of HIV and Viral Hepatitis Coinfections in Liver Transplantation
 

Hepat Med. 2022 Apr 29;14:27-36. doi: 10.2147/HMER.S282662. eCollection 2022.

Josiah D McCain 1, David M Chascsa 2
 
101.A Review of the Metabolism and Potential Drug-drug Interactions With Addictive Drugs
 

J Addict Med. 2022 Jan-Feb 01;16(1):e30-e39.doi: 10.1097/ADM.0000000000000824.

Joshua Radke 1, Kelly Tocki, Brett A Faine
 
102.Barriers and facilitators to hepatitis C screening and treatment for people with lived experience of homelessness: A mixed-methods systematic review
 

Health Expect. 2022 Feb;25(1):48-60. doi: 10.1111/hex.13400. Epub 2021 Dec 3.

Martha Paisi 1 2, Neeltje Crombag 3, Lorna Burns 2, Annick Bogaerts 1 4 5, Lyndsey Withers 6, Laura Bates 7, Daniel Crowley 8, Robert Witton 2, Jill Shawe 1 9
 
103.The Hepatitis C Clinical Exchange Network: A Local Health Department Partnership With Acute Care Hospitals to Promote Screening and Treatment of Hepatitis C Virus Infection
 

Nadine Kela-Murphy 1, Miranda S Moore, Charu M Verma, Marie P Bresnahan, Emily Harrison, Jessie Schwartz, Ann Winters
 
104.The Hepatitis C Clinical Exchange Network: A Local Health Department Partnership With Acute Care Hospitals to Promote Screening and Treatment of Hepatitis C Virus Infection
 

J Public Health Manag Pract. 2022 Mar-Apr 01;28(2):E413-E420.doi: 10.1097/PHH.0000000000001402.

Nadine Kela-Murphy 1, Miranda S Moore, Charu M Verma, Marie P Bresnahan, Emily Harrison, Jessie Schwartz, Ann Winters
 
105.Similarities, differences, and possible interactions between hepatitis E and hepatitis C viruses: Relevance for research and clinical practice
 

World J Gastroenterol. 2022 Mar 28;28(12):1226-1238.doi: 10.3748/wjg.v28.i12.1226.

Nadia Marascio 1, Salvatore Rotundo 2, Angela Quirino 1, Giovanni Matera 1, Maria Carla Liberto 1, Chiara Costa 2, Alessandro Russo 2, Enrico Maria Trecarichi 2, Carlo Torti 3
 
106.Staging Fibrosis in Chronic Viral Hepatitis
 

Viruses. 2022 Mar 23;14(4):660. doi: 10.3390/v14040660.

Ana Carolina Cardoso 1, Claudio Figueiredo-Mendes 2, Cristiane A Villela-Nogueira 3, Patrick Marcellin 4
 
107.Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: A clinical experience and a literature review
 

World J Hepatol. 2022 Mar 27;14(3):525-534. doi: 10.4254/wjh.v14.i3.525.

Anna Maria Spera 1
 
108.Reaching people receiving opioid agonist therapy at community pharmacies with hepatitis C virus: an international randomised controlled trial
 

Aliment Pharmacol Ther. 2022 Jun;55(12):1512-1523.doi: 10.1111/apt.16953. Epub 2022 May 10.

Christopher J Byrne 1 2, Andrew Radley 3, Sarah K Inglis 2, Lewis Beer 2, Nicki Palmer 4, Minh Duc Pham 5 6, Kate Allardice 6, Huan Wang 7, Emma Robinson 8, Monika Hermansson 9, Dimitri Semizarov 9, Brendan Healy 4, Joseph S Doyle 5 6, John F Dillon 1 8
 
109.Closing the hepatitis C treatment gap: United States strategies to improve retention in care
 

J Viral Hepat. 2022 May 12. doi: 10.1111/jvh.13685. Online ahead of print.

Austin T Jones 1, Christopher Briones 2, Torrence Tran 2, Lisa Moreno-Walton 3, Patricia J Kissinger 4
 
110.The use of technology-based adherence monitoring in the treatment of hepatitis C virus
 

Ther Adv Infect Dis. 2022 May 13;9:20499361221095664.doi: 10.1177/20499361221095664. eCollection Jan-Dec 2022.

Yeba H Adje 1, Kristina M Brooks 1, Jose R Castillo-Mancilla 2, David L Wyles 2, Peter L Anderson 1, Jennifer J Kiser 3
 
111.The Use of Hepatitis C Virus-Positive Organs in Hepatitis C Virus-Negative Recipients
 

Clin Liver Dis. 2022 May;26(2):291-312. doi: 10.1016/j.cld.2022.01.012.Epub 2022 Apr 1.

Christian Kuntzen 1, Zohaib Bagha 2
 
112.Clinical outcomes of sofosbuvir-based antivirals in patients with COVID-19: a systematic review and meta-analysis of randomized trials
 

Expert Rev Anti Infect Ther. 2022 Apr;20(4):567-575.doi: 10.1080/14787210.2022.2000861. Epub 2021 Nov 25.

Chia Siang Kow 1, Amaan Javed 2, Dinesh Ramachandram 1, Syed Shahzad Hasan 3 4
 
113.People who inject drugs in metropolitan Chicago: A meta-analysis of data from 1997-2017 to inform interventions and computational modeling toward hepatitis C microelimination
 

PLoS One. 2022 Jan 12;17(1):e0248850. doi: 10.1371/journal.pone.0248850.eCollection 2022.

Basmattee Boodram 1, Mary Ellen Mackesy-Amiti 1, Aditya Khanna 2, Bryan Brickman 3, Harel Dahari 4, Jonathan Ozik 5
 
114.Integrating Management of Hepatitis C Infection into Primary Care: the Key to Hepatitis C Elimination Efforts
 

J Gen Intern Med. 2022 Apr 28. doi: 10.1007/s11606-022-07628-9.Online ahead of print.

Allison E Wang 1, Eric Hsieh 1, Barbara J Turner 1, Norah Terrault 2 3
 
115.Predictors of 007 triphosphate concentrations in dried blood spots in persons with hepatitis C and active drug or alcohol use
 

 Antimicrob Chemother. 2022 Apr 27;77(5):1396-1403.doi: 10.1093/jac/dkac051.

Kristina M Brooks 1, Jose R Castillo-Mancilla 2, Mary Morrow 3, Samantha Mawhinney 3, Sarah E Rowan 2 4, David Wyles 2 4, Joshua Blum 4, Ryan Huntley 1, Lana Salah 1, Arya Tehrani 1, Leah C Jimmerson 1, Laura Roon 1, Lane R Bushman 1, Peter L Anderson 1, Jennifer J Kiser 1
 
116.Population-Based Testing for Undiagnosed Hepatitis C: A Systematic Review of Economic Evaluations
 

Appl Health Econ Health Policy. 2022 Mar;20(2):171-183. doi: 10.1007/s40258-021-00694-w.Epub 2021 Dec 6.

Paul G Carty 1 2, Christopher G Fawsitt 3, Paddy Gillespie 4, Patricia Harrington 3, Michelle O'Neill 3, Susan M Smith 5, Conor Teljeur 3, Mairin Ryan 3 6
 
117.Long-Term Hepatocellular Carcinoma Development and Predictive Ability of Non-Invasive Scoring Systems in Patients with HCV-Related Cirrhosis Treated with Direct-Acting Antivirals
 

Cancers (Basel). 2022 Feb 6;14(3):828. doi: 10.3390/cancers14030828.

Gian Paolo Caviglia 1, Giulia Troshina 1, Umberto Santaniello 1, Giulia Rosati 1, Francesco Bombaci 1, Giovanni Birolo 1, Aurora Nicolosi 1, Giorgio Maria Saracco 1 2, Alessia Ciancio 1 2
 
118.A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial
 

Lancet Gastroenterol Hepatol. 2022 Apr;7(4):307-317.doi: 10.1016/S2468-1253(21)00397-6. Epub 2022 Jan 10.

Sunil S Solomon 1, Sandra Wagner-Cardoso 2, Laura Smeaton 3, Leonard A Sowah 4, Chanelle Wimbish 5, Gregory Robbins 6, Irena Brates 3, Christine Scello 7, Annie Son 8, Anchalee Avihingsanon 9, Benjamin Linas 10, Donald Anthony 11, Estevão Portela Nunes 2, Dimas A Kliemann 12, Khuanchai Supparatpinyo 13, Cissy Kityo 14, Pablo Tebas 15, Jaclyn Ann Bennet 16, Jorge Santana-Bagur 17, Constance A Benson 18, Marije Van Schalkwyk 19, Nelson Cheinquer 8, Susanna Naggie 20, David Wyles 21, Mark Sulkowski 22
 
119.Hepatitis D virus dual infection increased the risk of hepatocellular carcinoma compared with hepatitis B virus mono infection: A meta-analysis
 

 Chin Med Assoc. 2022 Jan 1;85(1):30-41.doi: 10.1097/JCMA.0000000000000606.

Tien-En Chang 1 2 3, Chien-Wei Su 1 2 4, Yi-Shin Huang 1 2, Yi-Hsiang Huang 1 5, Ming-Chih Hou 1 2, Jaw-Ching Wu 6 5 7
 
120.Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response
 

Clin Gastroenterol Hepatol. 2022 Feb;20(2):438-446.doi: 10.1016/j.cgh.2021.01.026. Epub 2021 Jan 22.

Zobair M Younossi 1, Andrei Racila 2, Andrew Muir 3, Marc Bourliere 4, Alessandra Mangia 5, Rafael Esteban 6, Stefan Zeuzem 7, Massimo Colombo 8, Michael Manns 9, George V Papatheodoridis 10, Maria Buti 6, Anand Chokkalingam 11, Anuj Gaggar 11, Fatema Nader 12, Issah Younossi 12, Linda Henry 12, Maria Stepanova 12
 
121.Laboratory-based testing for hepatitis C infection using dried blood spot samples: A systematic review and meta-analysis of diagnostic accuracy
 

Rev Med Virol. 2021 Dec 26;e2320. doi: 10.1002/rmv.2320. Online ahead of print.

Paul G Carty 1 2, Michael McCarthy 2, Sinéad M O'Neill 2, Cillian F De Gascun 3, Patricia Harrington 2, Michelle O'Neill 2, Susan M Smith 4, Conor Teljeur 2, Mairin Ryan 2 5
 
122.The management of infants, children, and youth at risk for hepatitis C virus infection
 

Paediatr Child Health. 2021 Nov 11;26(7):440-441. doi: 10.1093/pch/pxab073.eCollection 2021 Nov.

Ari Bitnun 1
 
123.Hepatitis C: Current State of Treatment in Children
 

Pediatr Clin North Am. 2021 Dec;68(6):1321-1331. doi: 10.1016/j.pcl.2021.07.008.

Sanu R Yadav 1, Deborah A Goldman 1, Karen F Murray 2
 
124.The curing regimens of HCV: A SWOT analysis
 

Antivir Ther. Feb-Apr 2022;27(1-2):13596535211072672. doi: 10.1177/13596535211072672.

Markus Cornberg 1 2 3, Michael P Manns 4
 
125.Prevalence of hepatitis C in sexual assault survivors presenting to a SANE clinic: A descriptive analysis
 

 Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13675. Online ahead of print.

Erin Ward 1, Nicholas Carlisle 2, Ebony Williams 2, Sonya L Heath 3, Kellie Meloun 4, Lauren A Walter 5
 
126.Community pharmacist engagement in HIV and HCV prevention: Current practices and potential for service uptake
 

Explor Res Clin Soc Pharm. 2021 Oct 28;4:10008 doi: 10.1016/j.rcsop.2021.100088.eCollection 2021 Dec.

KariLynn Dowling-McClay 1, Stephanie M Mathis 2, Nicholas Hagemeier 1
 
127.Nurse practitioners as primary care site champions for the screening and treatment of hepatitis C virus
 

J Am Assoc Nurse Pract. 2022 Jan 21;34(4):688-695. doi: 10.1097/JXX.0000000000000689.

Cheryl H Dale 1, Elizabeth Smith 1 2, Mia J Biondi 1 3
 
128.HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis
 

Hepatology. 2022 Jan 14. doi: 10.1002/hep.32341. Online ahead of print.

Ian Lockart 1 2, Malcolm G H Yeo 1, Behzad Hajarizadeh 3, Gregory J Dore 2 3, Mark Danta 1 2
 
129.Global incidence and mortality of hepatitis B and hepatitis C acute infections, cirrhosis and hepatocellular carcinoma from 2010 to 2019
 

J Viral Hepat. 2022 May;29(5):352-365. doi: 10.1111/jvh.13663. Epub 2022 Mar 15.

Nicolette Veracruz 1, Robert G Gish 2, Ramsey Cheung 3 4, Amit S Chitnis 5, Robert J Wong 3 4
 
130.Epidemiology of Hepatitis C virus infection among incarcerated populations in North Dakota
 

PLoS One. 2022 Mar 29;17(3):e0266047. doi: 10.1371/journal.pone.0266047. eCollection 2022.

Liton Chandra Deb 1 2, Hannah Hove 1 3, Tracy K Miller 4, Kodi Pinks 4, Grace Njau 4, John J Hagan 5, Rick J Jansen 1 6 7 8
 
131.Micro-elimination of hepatitis C in people who use injectable drugs along the USA-Mexico border: a modelling study
 

Lancet Glob Health. 2022 Mar;10 Suppl 1:S6. doi: 10.1016/S2214-109X(22)00135-8.

Lara K Marquez 1, Clara Fleiz 2, Carlos Magis-Rodriguez 3, Natasha K Martin 4
 
132.Individualized Provider Feedback Increased HIV and HCV Screening and Identification in a New York City Emergency Department
 

AIDS Patient Care STDS. 2022 Mar;36(3):106-114. doi: 10.1089/apc.2021.0225.

Jason Zucker 1, Lawrence Purpura 1 2, Fereshteh Sani 3, Simian Huang 1, Aaron Schluger 4, Kenneth Ruperto 5, Jacek Slowkowski 5, Susan Olender 1, Matt Scherer 1, Delivette Castor 1, Peter Gordon 1
 
133.Feasibility of hepatitis C virus testing and linkage in community supervision offices: Great potential but persistent challenges
 

Int J Drug Policy. 2022 Mar 31;103:103668. doi: 10.1016/j.drugpo.2022.103668.Online ahead of print.

Brendan P Jacka 1, Laurie B Bazerman 2, Collin Dickerson 3, Marc Moody 4, Johanna Martin 2, Emily Patry 2, Treniece Cady 2, Hacheming Compere 2, Matthew Boudreau 2, Curt G Beckwith 5
 
134.A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study
 

Hepatology. 2021 Dec;74(6):2952-2964.doi: 10.1002/hep.32053.Epub 2021 Aug 26.

Mark S Sulkowski 1, Juhi S Moon 1, Kenneth E Sherman 2, Giuseppe Morelli 3, Jama M Darling 4, Andrew J Muir 5, Mandana Khalili 6, Dawn A Fishbein 7, Federico Hinestrosa 8, Mitchell L Shiffman 9, Adrian Di Bisceglie 10, K Rajender Reddy 11, Brian Pearlman 12, Anna S Lok 13, Michael W Fried 4, Paul W Stewart 14, Joy Peter 3, Summer Wadsworth 15, Scott Kixmiller 16, Anquenette Sloan 17, Monika Vainorius 4, Patrick M Horne 3, Larry Michael 14, Meichen Dong 14, Donna M Evon 4, Jodi B Segal 18, David R Nelson 3, PRIORITIZE Study Team
 
135.Patient-centered HCV care via telemedicine for individuals on medication for opioid use disorder: Telemedicine for Evaluation, Adherence and Medication for Hepatitis C (TEAM-C)
 

Contemp Clin Trials. 2022 Jan;112:106632.doi: 10.1016/j.cct.2021.106632. Epub 2021 Nov 20.

Andrew H Talal 1, Marianthi Markatou 2, Elisavet M Sofikitou 3, Lawrence S Brown 4, Ponni Perumalswami 5, Amreen Dinani 6, Jonathan N Tobin 7
 
136.Diagnosis of hepatitis C infection and cascade of care in the active component, U.S. Armed Forces, 2020
 

MSMR. 2022 Feb 1;29(2):2-7.

Mitchell Legg, Nicholas Seliga, Heather Mahaney, Todd Gleeson, James Mancuso
 
137.Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension
 

Infect Dis Ther. 2022 Apr;11(2):913-924. doi: 10.1007/s40121-022-00599-8. Epub 2022 Feb 17.

Robert S Brown Jr 1, Michelle A Collins 2, Simone I Strasser 3, Amanda Emmett 2, Andrew S Topp 2, Margaret Burroughs 2, Rosa Ferreira 2, Jordan J Feld 4
 
138.Hepatitis C Virus Direct-Acting Antiviral Treatment Adherence Patterns and Sustained Viral Response Among People Who Inject Drugs Treated in Opioid Agonist Therapy Programs
 

Clin Infect Dis. 2021 Dec 6;73(11):2093-2100.doi: 10.1093/cid/ciab334.

Moonseong Heo 1, Irene Pericot-Valverde 2, Lior Rennert 1, Matthew J Akiyama 3, Brianna L Norton 3, Mirinda Gormley 1, Linda Agyemang 3, Julia H Arnsten 3, Alain H Litwin 2 4 5
 
139.Formal Hepatitis C Education Increases Willingness to Receive Therapy in an On-site Shelter-Based HCV Model of Care in Persons Experiencing Homelessness
 

Open Forum Infect Dis. 2022 Mar 1;9(4):ofac103. doi: 10.1093/ofid/ofac103.eCollection 2022 Apr.

Diana Partida 1, Jesse Powell 2, Margaret Ricco 2, Jessica Naugle 3, Catherine Magee 4, Barry Zevin 3, Carmen L Masson 5, J Konadu Fokuo 5, Daniel Gonzalez 6 7, Mandana Khalili 6 7
 
140.Emergency department versus community screening on hepatitis C follow-up care
 

Am J Emerg Med. 2022 Mar 24;56:151-157. doi: 10.1016/j.ajem.2022.03.041.Online ahead of print.

Austin T Jones 1, Lisa Moreno-Walton 2, Torrence Tran 3, Christopher Briones 3, Kanayo Okeke-Eweni 2, Rachael Stevens 4, Kacie Isaacson 5, Hua He 6, Patricia J Kissinger 6
 
141.Implementation of HCV screening in the 1969-1989 birth-cohort undergoing COVID-19 vaccination
 

Liver Int. 2022 Feb 27. doi: 10.1111/liv.15216. Online ahead of print.

Roberta D'Ambrosio 1, Giuliano Rizzardini 2, Massimo Puoti 3, Stefano Fagiuoli 4, Maria Paola Anolli 1, Claudia Gabiati 5, Federico D'Amico 3, Luisa Pasulo 4, Umberto Restelli 6 7, Massimo Colombo 8, Pietro Lampertico 1 9
 
142.Long-term Follow-up of Hepatitis C Patients Who Achieved Sustained Virologic Response in the Pragmatic PRIORITIZE Study
 

Clin Gastroenterol Hepatol. 2022 Feb 17;S1542-3565(22)00179-3.doi: 10.1016/j.cgh.2022.01.059. Online ahead of print.

Anna S Lok 1, Juhi Moon 2, Kenneth E Sherman 3, Mandana Khalili 4, Dawn Fishbein 5, K Rajender Reddy 6, PRIORITIZE Study Team
 
143.Outcomes of Adult Liver Retransplantation: A Canadian National Database Analysis
 

Can J Gastroenterol Hepatol. 2022 Mar 22;2022:9932631. doi: 10.1155/2022/9932631.eCollection 2022.

Peter D Yoon 1 2, Madhukar S Patel 1 3, Carla F Murillo Perez 4, Tommy Ivanics 1 5 6, Marco P A W Claasen 1 7, Hala Muaddi 1, David Wallace 1 8 9, Bettina Hansen 4 10, Gonzalo Sapisochin 1
 
144.Durability of sustained virological response to glecaprevir/pibrentasvir and resistance development: A long-term follow-up study
 

Liver Int. 2022 Feb 26. doi: 10.1111/liv.15211. Online ahead of print.

Fred Poordad 1, Franco Felizarta 2, Betty B Yao 3, J Scott Overcash 4, Tarek Hassanein 5, Kosh Agarwal 6, Edward Gane 7, David Shaw 8, Michael Waters 4, Preethi Krishnan 3, Andrew Topp 3, Margaret Burroughs 3, Frederik Nevens 9
 
145.A global systematic review of hepatitis C elimination efforts through micro-elimination
 

Semin Liver Dis. 2022 Feb 21. doi: 10.1055/a-1777-6112. Online ahead of print.

Jeffrey V Lazarus 1 2, Camila A Picchio 2, Christopher Byrne 3, Javier Crespo 4, Massimo Colombo 5, Graham Cooke 6, Gregory J Dore 7, Jason Grebely 7, John W Ward 8, John Dillon 9 3
 
146.Prevalence and outcomes of chronic liver disease in patients receiving dialysis: systematic review and meta-analysis
 

Clin Kidney J. 2021 Nov 18;15(4):747-757. doi: 10.1093/ckj/sfab230. eCollection 2022 Apr.

Oscar Swift 1, Shivani Sharma 2, Sivaramakrishnan Ramanarayanan 1, Hamza Umar 3, Keith R Laws 2, Enric Vilar 1, Ken Farrington 1
 
147.Hepatitis C: Standard of Treatment and What to Do for Global Elimination
 

Viruses. 2022 Feb 28;14(3):505. doi: 10.3390/v14030505.

Lorenza Di Marco 1 2, Claudia La Mantia 3, Vito Di Marco 3
 
148.Removal of medicaid restrictions were associated with increased hepatitis C virus treatment rates, but disparities persist
 

J Viral Hepat. 2022 Mar 7. doi: 10.1111/jvh.13661. Online ahead of print.

Lauren D Nephew 1 2, Yumin Wang 3, Kawthar Mohamed 4, Deborah Nichols 5, Susan M Rawl 2 6, Eric Orman 1, Archita P Desai 1, Kavish R Patidar 1, Marwan Ghabril 1, Naga Chalasani 1, Monica L Kasting 2 7
 
149.Treatment-Resistant Hepatitis C Viral Infection: A Case Report and Literature Review
 

Case Reports Hepato. 2022 Mar 11;2022:3556780.doi: 10.1155/2022/3556780. eCollection 2022.

Victoria Green 1, Marina Roytman 2
 
150.Knowledge of hepatitis C and awareness of reinfection risk among people who successfully completed direct acting antiviral therapy
 

PLoS One. 2022 Mar 23;17(3):e0265811. doi: 10.1371/journal.pone.0265811. eCollection 2022.

Kiana Yazdani 1, Katerina Dolguikh 1, Wendy Zhang 1, Sara Shayegi-Nik 1 2, Jessica Ly 1, Shaughna Cooper 1, Jason Trigg 1, Sophia Bartlett 3 4, Rolando Barrios 1 3, Julio S G Montaner 1, Kate Salters 1 5
 
151.The Importance of Prisons in Achieving Hepatitis C Elimination: Insights from the Australian Experience
 

Viruses. 2022 Feb 28;14(3):497. doi: 10.3390/v14030497.

Rebecca J Winter 1 2 3, Jacinta A Holmes 2 4, Timothy J Papaluca 2 4, Alexander J Thompson 2 4
 
152.Sustained impact of the COVID-2019 pandemic on HCV treatment initiations in the United States
 

Clin Infect Dis. 2022 Mar 2;ciac175. doi: 10.1093/cid/ciac175. Online ahead of print.

Martin Hoenigl 1 2, Daniela Abramovitz 1, Ricardo E Flores Ortega 1, Natasha K Martin 1 3, Nancy Reau 4
 
153.The impact of point-of-care hepatitis C testing in needle and syringe exchange programs on linkage to care and treatment uptake among people who inject drugs: An Australian pilot study
 

J Viral Hepat. 2022 Mar 11. doi: 10.1111/jvh.13664. Online ahead of print.

Jessica Howell 1 2 3 4, Michael W Traeger 1 2, Bridget Williams 1, Chloe Layton 5, Joseph S Doyle 1 6, Ned Latham 1 7, Bridget Draper 1 2, Frances Bramwell 5, Dean Membrey 5, Maggie Mcpherson 8, Janine Roney 9, Mark Stoové 1, Alexander J Thompson 3 4, Margaret E Hellard 1 2 6 10, Alisa Pedrana 1 2
 
154.Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis
 

Lancet Gastroenterol Hepatol. 2022 Mar 15;S2468-1253(21)00471-4.doi: 10.1016/S2468-1253(21)00471-4. Online ahead of print.

Evan B Cunningham 1, Alice Wheeler 2, Behzad Hajarizadeh 2, Clare E French 3, Rachel Roche 4, Alison D Marshall 5, Guillaume Fontaine 6, Anna Conway 5, Braulio M Valencia 2, Sahar Bajis 2, Justin Presseau 7, John W Ward 8, Louisa Degenhardt 9, Gregory J Dore 2, Matthew Hickman 10, Peter Vickerman 10, Jason Grebely 2
 
155.Detection of Recurrent Hepatitis C Viremia Using Surveillance Data, New York City
 

J Public Health Manag Pract. 2022 Mar-Apr 01;28(2):126-129.doi: 10.1097/PHH.0000000000001150.

Kevin Guerra 1, Angelica Bocour, Miranda S Moore, Ann Winters
 
156.Low Utilization of Direct-Acting Antiviral Agents in a Large National Cohort of HIV and HCV Coinfected Medicare Patients in the United States: Implications for HCV Elimination
 

J Public Health Manag Pract. 2022 Mar-Apr 01;28(2):130-134.doi: 10.1097/PHH.0000000000001147.

Ping Du 1, Jeah Jung, Yamini Kalidindi, Kevin Farrow, Thomas Riley 3rd, Cynthia Whitener
 
157.Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral based treatment regimens: evidence from a global dataset
 

J Viral Hepat. 2022 Mar 12. doi: 10.1111/jvh.13672. Online ahead of print.

Jake R Morgan 1, Elizabeth Marsh 2, Alexandra Savinkina 2, Sonjelle Shilton 3, Shaun Shadaker 4, Tengiz Tsertsvadze 5, George Kamkamidze 6, Maia Alkhazashvili 7, Tim Morgan 8, Pam Belperio 8, L Backus 8, Waheed Doss 9, Gamal Esmat 9, Mohamed Hassany 9, Aisha Elsharkawy 9, Wafaa Elakel 9, Mai Mehrez 9, Graham R Foster 10, Kinge Wose 11, Kara W Chew 12, Charles S Chasela 13, Ian M Sanne 14, Yin M Thanung 15, Anne Loarec 16, Khawar Aslam 17, Suna Balkan 18, Philippa J Easterbrook 19, Benjamin P Linas 2 20
 
158.The Payer License Agreement, or "Netflix model," for hepatitis C virus therapies enables universal treatment access, lowers costs, and incentivizes innovation and competition
 

Liver Int. 2022 Mar 15. doi: 10.1111/liv.15245. Online ahead of print.

David W Matthews 1 2, Samantha Coleman 3, Homie Razavi 3, Jean-Manuel Izaret 1 2
 
159.Accessible Hepatitis C Care for People Who Inject Drugs: A Randomized Clinical Trial
 

JAMA Intern Med. 2022 Mar 14. doi: 10.1001/jamainternmed.2022.0170. Online ahead of print.

Benjamin Eckhardt 1, Pedro Mateu-Gelabert 2, Yesenia Aponte-Melendez 2, Chunki Fong 2, Shashi Kapadia 3, Melinda Smith 3, Brian R Edlin 4 5, Kristen M Marks 3
 
160.The Association Between Self-Reported Non-Injection Cocaine Use and Hepatitis C in the United States: An Analysis of the National Health and Nutrition Examination Survey
 

J Stud Alcohol Drugs. 2022 Mar;83(2):195-201.

Alison E Simmons 1, Ania I Fiedler 2, David N Fisman 1, Susan J Bondy 1
 
161.High-Risk Injection-Related Practices Associated with anti-HCV Positivity among Young Adults Seeking Services in Three Small Cities in Wisconsin
 

Subst Use Misuse. 2022 Mar 4;1-9. doi: 10.1080/10826084.2022.2026964.Online ahead of print.

Jessica Rogers-Brown 1, Farah Sublett 2, Lauren Canary 1, David B Rein 2, Maithili Bhat 1, William W Thompson 1, Claudia Vellozzi 1, Alice Asher 1
 
162.Effect of a Default Order vs an Alert in the Electronic Health Record on Hepatitis C Virus Screening Among Hospitalized Patients: A Stepped-Wedge Randomized Clinical Trial
 

JAMA Netw Open. 2022 Mar 1;5(3):e222427. doi: 10.1001/jamanetworkopen.2022.2427.

Shivan J Mehta 1 2, Jessie Torgersen 1, Dylan S Small 3, Colleen P Mallozzi 4 5, John D McGreevey 3rd 1 4 5, Charles A L Rareshide 1 6, Chalanda N Evans 1 6, Mika Epps 4, David Stabile 4, Christopher K Snider 2 6, Mitesh S Patel 1 3 6 7 8
 
163.Incidence of, Risk Factors for, and Outcomes After Ascites in a Population-Based Cohort of Older Americans
 

Dig Dis Sci. 2022 Mar 9. doi: 10.1007/s10620-022-07454-3. Online ahead of print.

Elliot B Tapper 1, Zhe Zhao 2, Nik Mazumder 2, Neehar D Parikh 2
 
164.Real-world monitoring progress towards the elimination of hepatitis C virus in Australia using sentinel surveillance of primary care clinics; an ecological study of hepatitis C virus antibody tests from 2009 to 2019
 

Epidemiol Infect. 2021 Dec 6;150:e7. doi: 10.1017/S0950268821002624.

Anna Lee Wilkinson 1 2, Alisa Pedrana 1 2, Michael W Traeger 1 2, Jason Asselin 1, Carol El-Hayek 1, Long Nguyen 1, Victoria Polkinghorne 1, Joseph S Doyle 1 3, Alexander J Thompson 4 5, Jessica Howell 1 2 4 5, Nick Scott 1 2, Wayne Dimech 6, Rebecca Guy 7, Margaret Hellard 1 2 3 8, Mark Stoové 1 2, EC Victoria Partnership and the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of blood-borne viruses AND sexually transmissible infections (ACCESS)
 
165.Does Preoperative Antiviral Treatment for Hepatitis C Decrease Risk of Complications After Total Hip Arthroplasty? A Matched Cohort Study
 

Arthroplasty. 2022 Mar 3;S0883-5403(22)00253-4. doi: 10.1016/j.arth.2022.02.102.Online ahead of print.

Austin J Ross 1, Bailey J Ross 1, Olivia C Lee 2, Hunter W Hood 1, Fernando L Sanchez 1, William F Sherman 3
 
166.Statewide Assessment of the Hepatitis C Virus Care Cascade for Incarcerated Persons in Vermont
 

Public Health Rep. 2022 Mar 9;333549221077070. doi: 10.1177/00333549221077070.Online ahead of print.

Andrew J Hale 1 2, Shivani Mathur 2, Jean Dejace 1 2, Steven D Lidofsky 1 2
 
167.In the Era of Direct-Acting Antivirals, Liver Transplant Delisting Due to Clinical Improvement for Hepatitis C Remains Infrequent
 

Clin Gastroenterol Hepatol. 2021 Nov;19(11):2389-2397.e2. doi: 10.1016/j.cgh.2020.09.033.Epub 2020 Sep 21.

Therese Bittermann 1, K Rajender Reddy 2
 
168.Microelimination of Hepatitis C Among People With Human Immunodeficiency Virus Coinfection: Declining Incidence and Prevalence Accompanying a Multicenter Treatment Scale-up Trial
 

Clin Infect Dis. 2021 Oct 5;73(7):e2164-e2172. doi: 10.1093/cid/ciaa1500.

Joseph S Doyle 1 2, Daniela K van Santen 1 3, David Iser 2 4, Joe Sasadeusz 2 5, Mark O'Reilly 6, Brendan Harney 1 2, Michael W Traeger 1 3, Janine Roney 2, Julia C Cutts 1, Anna L Bowring 1, Rebecca Winter 1 4, Nick Medland 7, Christopher K Fairley 7, Richard Moore 8, B K Tee 9, Jason Asselin 1, Carol El-Hayek 1, Jennifer F Hoy 2, Gail V Matthews 10, Maria Prins 11 12, Mark A Stoové 1 3, Margaret E Hellard 1 2 3 13
 
169.Hepatitis C Epidemiology in a Large Urban Jail: A Changing Demographic
 

Public Health Rep. 2022 Mar 3;333549221076546. doi: 10.1177/00333549221076546.Online ahead of print.

Emily Hoff 1, Andrea Warden 2, Ruby Taylor 2, Ank E Nijhawan 1 2
 
170.Sofosbuvir and risk of estimated glomerular filtration rate decline or end-stage renal disease in patients with renal impairment
 

Aliment Pharmacol Ther. 2022 Mar 2. doi: 10.1111/apt.16830. Online ahead of print.

Mark Sulkowski 1, Laura E Telep 2, Massimo Colombo 3, Francois Durand 4, K Rajender Reddy 5, Eric Lawitz 6, Marc Bourlière 7 8, Nelson Cheinquer 2, Stacey Scherbakovsky 2, Liyun Ni 2, Lindsey Force 2, Heribert Ramroth 2, Anuj Gaggar 2, Anand P Chokkalingam 2, Meghan E Sise 9
 
171.Outcomes of community-based hepatitis C treatment by general practitioners and nurses in Australia through remote specialist consultation
 

Intern Med J. 2021 Nov;51(11):1927-1934. doi: 10.1111/imj.15037. Epub 2021 Oct 28.

James Haridy 1 2 3, Guru Iyngkaran 1 2 4, Amanda Nicoll 1 3 5, Kate Muller 6, Mark Wilson 7, Alan Wigg 6, Jeyamani Ramachandran 6, Renjy Nelson 8 9, Stephen Bloom 3 5, Joseph Sasadeusz 10, Sally Watkinson 10, Anton Colman 11, Rosalie Altus 6, Emma Tilley 6, Jeffrey Stewart 6 9, Geoff Hebbard 2, Danny Liew 12, Edmund Tse 8 11
 
172.Cost-effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States
 

Clin Infect Dis. 2021 Nov 2;73(9):e3355-e3357. doi: 10.1093/cid/ciaa362.

Antoine Chaillon 1, Adriane Wynn 1, Tatyana Kushner 2, Nancy Reau 3, Natasha K Martin 1 4
 
173.You Can't Have One Without the Other: Innovation and Ethical Dilemmas in Gastroenterology and Hepatology
 

Clin Gastroenterol Hepatol. 2021 Oct;19(10):2015-2019.doi: 10.1016/j.cgh.2020.05.024. Epub 2020 May 20.

Thomas Couri 1, Andrew Aronsohn 2
 
174.Educating Primary Care Providers and Associate Care Providers About Hepatitis C Screening of Baby Boomers: a Multi-practice Study
 

J Cancer Educ. 2022 Feb;37(1):217-223. doi: 10.1007/s13187-020-01805-2.

Bertha E Flores 1, Andrea A Fernandez 1, Chen-Pin Wang 2 3, Raudel Bobadilla 3, Ludivina Hernandez 3, Mamta K Jain 4, Barbara J Turner 5
 
175.Nucleic Acid Testing for Diagnosis of Perinatally Acquired Hepatitis C Virus Infection in Early Infancy
 

Clin Infect Dis. 2021 Nov 2;73(9):e3340-e3346. doi: 10.1093/cid/ciaa949.

Charitha Gowda 1 2, Stephanie Smith 1, Linda Crim 1, Katherine Moyer 3, Pablo J Sánchez 1 4 5, Jonathan R Honegger 1 6
 
176.Cost-effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States
 

Clin Infect Dis. 2021 Nov 2;73(9):e3355-e3357. doi: 10.1093/cid/ciaa362.

Antoine Chaillon 1, Adriane Wynn 1, Tatyana Kushner 2, Nancy Reau 3, Natasha K Martin 1 4
 
177.New hope for hepatitis C virus: Summary of global epidemiologic changes and novel innovations over 20 years
 

World J Gastroenterol. 2021 Aug 7;27(29):4818-4830.doi: 10.3748/wjg.v27.i29.4818.

Brittany B Dennis 1, Leen Naji 2, Yasmin Jajarmi 1, Aijaz Ahmed 3, Donghee Kim 4
 
178.Treatment of hepatitis C virus infection in people with opioid use disorder: a real-world study of elbasvir/grazoprevir in a US Department of Veterans Affairs population
 

Am J Drug Alcohol Abuse. 2022 Jan 25;1-9. doi: 10.1080/00952990.2021.1983821.Online ahead of print.

Jennifer R Kramer 1 2, Amy Puenpatom 3, Yumei Cao 1, Xian Yu 2, Hashem B El-Serag 1 2, Fasiha Kanwal 1 2
 
179.Hepatitis C Testing and Linkage to Care Among Adults on Probation in a Large US City
 

Open Forum Infect Dis. 2021 Dec 16;9(2):ofab636. doi: 10.1093/ofid/ofab636.eCollection 2022 Feb.

Kevin F Kamis 1, David L Wyles 2, Matthew S Minturn 3, Tracy Scott 4, Dean McEwen 1, Hermione Hurley 1 2 5, Scott J Prendergast 6, Sarah E Rowan 1 2
 
180.Sofosbuvir-Velpatasvir-Voxilaprevir in Adolescents 12 to 17 Years Old With Hepatitis C Virus Infection
 

Hepatology. 2022 Feb 3. doi: 10.1002/hep.32393. Online ahead of print.

Guiseppe Indolfi 1, Deirdre Kelly 2, Gabriella Nebbia 3, Raffaele Iorio 4, Anna Mania 5, Vania Giacomet 6, Leszek Szenborn 7, Jiang Shao 8, Mun Sang Yue 8, Chia-Hsiang Hsueh 8, Bandita Parhy 8, Kathryn Kersey 8, Alessandra Mangia 9, Malgorzata Pawlowska 10, Sanjay Bansal 11
 
181.Mortality among Alaska Native Adults with Confirmed Hepatitis C Virus Infection Compared with the General Population in Alaska, 1995-2016
 

Can J Gastroenterol Hepatol. 2022 Feb 8;2022:2573545. doi: 10.1155/2022/2573545.eCollection 2022.

Sara S Bressler 1, Dana Bruden 1, Leisha D Nolen 1, Michael G Bruce 1, Lisa Towshend-Bulson 2, Philip Spradling 3, Brian J McMahon 1 2
 
182.Hepatitis C Vaccination: Where We Are and Where We Need to Be
 

Pathogens. 2021 Dec 14;10(12):1619. doi: 10.3390/pathogens10121619.

Vignan Manne 1, John Ryan 2, Jonathan Wong 1, Gayatri Vengayil 1, Syed Abdul Basit 2, Robert G Gish 3
 
183.Ledipasvir-sofosbuvir in Adolescents with Chronic Hepatitis C and Hematological Malignancies Undergoing Chemotherapy
 

J Pediatr Gastroenterol Nutr. 2022 Feb 10. doi: 10.1097/MPG.0000000000003406.Online ahead of print.

Manal Hamdy El-Sayed 1, Fatma S Elsayed Ebeid, Abdel-Rahman Zekri, Benedetta Massetto, Kathryn Kersey, Fangqiu Zhang, Anuj Gaggar, Walaa Elsayed, Alaa El-Haddad
 
184.Lower rates of emergency visits and hospitalizations among chronic hepatitis C patients with sustained virological response to interferon-free direct-acting antiviral therapy (2014-2018)
 

Clin Infect Dis. 2022 Feb 11;ciac124. doi: 10.1093/cid/ciac124. Online ahead of print.

Stuart C Gordon 1, Eyasu H Teshale 2, Philip R Spradling 2, Anne C Moorman 2, Joseph A Boscarino 3, Mark A Schmidt 4, Yihe G Daida 5, Loralee B Rupp 6, Sheri Trudeau 7, Jiaqi Zhang 7, Mei Lu 7, CHeCS Investigators
 
185.Comprehensive Comparative Analysis of Standard Validated, Genetic, and Novel Biomarkers to Enhance Prognostic Risk-stratification in Patients with Hepatitis C Cirrhosis
 

Clin Transl Gastroenterol. 2022 Feb 9. doi: 10.14309/ctg.0000000000000462.Online ahead of print.

Hamish Innes 1 2 3, Alex J Walker 4, Jennifer Benselin 5, Jane I Grove 5, Vincent Pedergnana 6 7, Shang-Kuan Lin 7, John McLauchlan 8, Sharon J Hutchinson 1 3, Eleanor Barnes 7, William L Irving 5, Indra Neil Guha 5, HCV Research UK; & STOP-HCV Consortia; HCV Research UK; & STOP-HCV Consortia
 
186.Hepatitis C virus micro-elimination within a clinic for people with HIV: challenges in the home stretch
 

HIV Med. 2022 Feb 12. doi: 10.1111/hiv.13241. Online ahead of print.

Jaklin Hanna 1, Jihan Sufian 1, Jin S Suh 1 2, Humberto R Jimenez 1 3
 
187.Global Utilization Trends of Direct Acting Antivirals (DAAs) during the COVID-19 Pandemic: A Time Series Analysis
 

Viruses. 2021 Jul 7;13(7):1314. doi: 10.3390/v13071314.

Ahmad Shakeri 1, Natalia Konstantelos 1 2, Cherry Chu 1, Tony Antoniou 3 4, Jordan Feld 5, Katie J Suda 6 7, Mina Tadrous 1 2
 
188.A Digital Case-Finding Algorithm for Diagnosed but Untreated Hepatitis C: A Tool for Increasing Linkage to Treatment and Cure
 

Hepatology. 2021 Dec;74(6):2974-2987. doi: 10.1002/hep.32086.

Brooke Wyatt 1, Ponni V Perumalswami 1 2 3, Anna Mageras 1, Mark Miller 1, Alyson Harty 1, Ning Ma 1, Chip A Bowman 4, Francina Collado 1, Jihae Jeon 1, Lismeiry Paulino 1, Amreen Dinani 1, Douglas Dieterich 1, Li Li 1, Maxence Vandromme 1, Andrea D Branch
 
189.A hepatitis C elimination model in healthcare for the homeless organization: A novel reflexive laboratory algorithm and equity assessment
 

Int J Drug Policy. 2021 Oct;96:103359. doi: 10.1016/j.drugpo.2021.103359. Epub 2021 Jul 27.

A Seaman 1, C A King 2, T Kaser 3, A Geduldig 3, W Ronan 3, R Cook 4, B Chan 5, X A Levander 4, K C Priest 6, P T Korthuis 4
 
190.Comparison of liver biopsies before and after direct-acting antiviral therapy for hepatitis C and correlation with clinical outcome
 

Sci Rep. 2021 Jul 15;11(1):14506. doi: 10.1038/s41598-021-93881-7.

Omar A Saldarriaga 1, Bradley Dye 2, Judy Pham 2, Timothy G Wanninger 2, Daniel Millian 2, Michael Kueht 3, Benjamin Freiberg 4, Netanya Utay 5, Heather L Stevenson 6 7
 
191.Care Facilitation Advances Movement Along the Hepatitis C Care Continuum for Persons With Human Immunodeficiency Virus, Hepatitis C, and Substance Use: A Randomized Clinical Trial (CTN-0064)
 

Open Forum Infect Dis. 2021 Jun 27;8(8):ofab334. doi: 10.1093/ofid/ofab334.eCollection 2021 Aug.

Lisa R Metsch 1, Daniel J Feaster 2, Lauren K Gooden 1, Carmen Masson 3, David C Perlman 4, Mamta K Jain 5, Tim Matheson 6, C Mindy Nelson 2, Petra Jacobs 7, Susan Tross 8, Louise Haynes 9, Gregory M Lucas 10, Jonathan A Colasanti 11, Allan Rodriguez 12, Mari-Lynn Drainoni 13, Georgina Osorio 4, Ank E Nijhawan 5, Jeffrey M Jacobson 14, Meg Sullivan 13, David Metzger 15, Pamela Vergara-Rodriguez 16, Ronald Lubelchek 17, Rui Duan 2, Jacob N Batycki 2, Abigail G Matthews 18, Felipe Munoz 18, Eve Jelstrom 19, Raul Mandler 20, Carlos Del Rio 11
 
192.Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial
 

Viruses. 2021 Jul 13;13(7):1351. doi: 10.3390/v13071351.

Christopher C Phelps 1, Christopher M Walker 1 2, Jonathan R Honegger 1 2
 
193.Trends of the Global Hepatitis C Disease Burden: Strategies to Achieve Elimination
 

J Prev Med Public Health. 2021 Jul;54(4):251-258. doi: 10.3961/jpmph.21.151. Epub 2021 Jun 24.

Nathalie Brunner 1, Philip Bruggmann 1 2
 
194.Hepatitis C Treatment Among Commercially or Medicaid-Insured Individuals, 2014-2018
 

Am J Prev Med. 2021 Nov;61(5):716-723. doi: 10.1016/j.amepre.2021.05.017. Epub 2021 Aug 3.

Aaron M Harris 1, Mohammed A Khan 2, Ademola Osinubi 2, Noele P Nelson 2, William W Thompson 2
 
195.Five-Year Follow-Up of Cured HCV Patients under Real-World Interferon-Free Therapy
 

2021 Jul 22;13(15):3694. doi: 10.3390/cancers13153694.

Robert Flisiak 1, Dorota Zarebska-Michaluk 2, Ewa Janczewska 3, Tadeusz Lapinski 1, Magdalena Rogalska 1, Ewa Karpinska 4, Tomasz Mikula 5, Beata Bolewska 6, Jolanta Bialkowska 7, Katarzyna Flejscher-Stepniewska 8, Krzysztof Tomasiewicz 9, Kornelia Karwowska 10, Monika Pazgan-Simon 11, Anna Piekarska 12, Hanna Berak 13, Olga Tronina 14, Aleksander Garlicki 15, Jerzy Jaroszewicz 16
 
196.A Systematic Review and Meta-Analysis of Studies Evaluating the Effect of Medication Treatment for Opioid Use Disorder on Infectious Disease Outcomes
 

Open Forum Infect Dis. 2021 Jun 2;8(8):ofab289. doi: 10.1093/ofid/ofab289.eCollection 2021 Aug.

Katelyn F McNamara 1, Breanne E Biondi 2, Raúl U Hernández-Ramírez 3 4, Noor Taweh 5 6, Alyssa A Grimshaw 7, Sandra A Springer 5 4
 
197.Reexamining Risk Aversion: Willingness to Pursue and Utilize Nonideal Donor Livers Among US Donation Service Areas
 

Transplant Direct. 2021 Aug 6;7(9):e742. doi: 10.1097/TXD.0000000000001173.eCollection 2021 Sep.

Samantha E Halpern 1, Mariya L Samoylova 2, Brian I Shaw 2, Samuel J Kesseli 2, Matthew G Hartwig 2, Yuval A Patel 3, Lisa M McElroy 2, Andrew S Barbas 2
 
198.'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs
 

Addict Sci Clin Pract. 2021 Aug 12;16(1):52. doi: 10.1186/s13722-021-00260-8.

Judith I Tsui 1, Michael P Barry 2 3, Elizabeth J Austin 4 5, Elsa W Sweek 4 5 6, Elyse Tung 7 8, Ryan N Hansen 7 8, Michael Ninburg 9, John D Scott 10, Sara N Glick 11 3, Emily C Williams 5 6
 
199.Prevalence of Hepatitis C Virus Infection Identified From Nontargeted Screening Among Adult Visitors in an Academic Appalachian Regional Emergency Department
 

Open Forum Infect Dis. 2021 Aug 4;8(8):ofab374. doi: 10.1093/ofid/ofab374.eCollection 2021 Aug.

J Daniel Moore 1, James Galbraith 2, Roger Humphries 1, Jennifer R Havens 3
 
200.Hepatitis C virus treatment with direct-acting antivirals induces rapid changes in the hepatic proteome
 

Viral Hepat. 2021 Nov;28(11):1614-1623. doi: 10.1111/jvh.13593. Epub 2021 Aug 19.

Lauren E Ball 1, Bernice Agana 1, Susana Comte-Walters 1, Don C Rockey 2, Henry Masur 3, Shyam Kottilil 4, Eric G Meissner 5 6
 
201.Medically treated opioid overdoses among New Jersey Medicaid beneficiaries: Rapid growth and complex comorbidity amid growing fentanyl penetration
 

J Subst Abuse Treat. 2021 Dec;131:108546. doi: 10.1016/j.jsat.2021.108546. Epub 2021 Jun 24.

Stephen Crystal 1, Molly Nowels 2, Mark Olfson 3, Hillary Samples 4, Arthur Robinson Williams 5, Peter Treitler 6
 
202.Partnering With State Health Departments to Address Injection-Related Infections During the Opioid Epidemic: Experience at a Safety Net Hospital
 

Open Forum Infect Dis. 2021 Apr 27;8(8):ofab208. doi: 10.1093/ofid/ofab208.eCollection 2021 Aug.

Rebecca H Burns 1, Cassandra M Pierre 2 3, Jai G Marathe 2 3, Glorimar Ruiz-Mercado 3 4, Jessica L Taylor 5 4, Simeon D Kimmel 3 5, Samantha L Johnson 3, H Dawn Fukuda 6, Sabrina A Assoumou 2 3
 
203.Validity of Self-Reported Hepatitis C Virus Status Among Criminal Justice-Involved Persons Living With HIV
 

J Correct Health Care. 2021 Sep;27(3):167-171. doi: 10.1089/jchc.19.05.0045. Epub 2021 Aug 18.

Amanda Noska 1 2 3, Tao Liu 4, Irene Kuo 5, Lauri Bazerman 2, Ann Kurth 6, Mia Coetzer 1, Rami Kantor 1 2, Curt Beckwith 1 2
 
204.Strategic treatment optimization for HCV (STOPHCV1): a randomized controlled trial of ultrashort duration therapy for chronic hepatitis C
 

Wellcome Open Res. 2021 Jul 29;6:93. doi: 10.12688/wellcomeopenres.16594.2.eCollection 2021.

Graham S Cooke 1 2, Sarah Pett 3 4 5, Leanne McCabe 3, Chris Jones 1 2, Richard Gilson 4 5, Sumita Verma 6, Stephen D Ryder 7, Jane D Collier 8, Stephen T Barclay 9, Aftab Ala 10, Sanjay Bhagani 11, Mark Nelson 12, Chinlye Ch'Ng 13, Ben Stone 14, Martin Wiselka 15, Daniel Forton 16, Stuart McPherson 17, Rachel Halford 18, Dung Nguyen 19, David Smith 19, Azim Ansari 19, Emily Dennis 3, Fleur Hudson 3, Eleanor J Barnes 19 20, Ann Sarah Walker 3
 
205.Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison
 

Int J Drug Policy. 2021 Oct;96:103394. doi: 10.1016/j.drugpo.2021.103394. Epub 2021 Aug 17.

Zoe Ward 1, Nyashadzaishe Mafirakureva 2, Jack Stone 2, Mary Keevans 3, Graham Betts-Symonds 4, Desmond Crowley 5, Tina McHugh 6, Gordana Avramovic 7, John S Lambert 8, Peter Vickerman 2
 
206.Changes in health-related quality of life for HCV-infected people who inject drugs on opioid agonist treatment following sustained virologic response
 

Clin Infect Dis. 2021 Jul 31;ciab669. doi: 10.1093/cid/ciab669.

Mirinda Ann Gormley 1, Matthew J Akiyama 2, Lior Rennert 1, Kerry A Howard 1, Brianna L Norton 2, Irene Pericot-Valverde 3, Sam Muench 2, Moonseong Heo 1, Alain H Litwin 3 4 5
 
207.Updated Pathway to Micro-elimination of Hepatitis C Virus in the Hemodialysis Population
 

Kidney Int Rep. 2021 Apr 25;6(7):1788-1798. doi: 10.1016/j.ekir.2021.04.015.eCollection 2021 Jul.

Arun Rajasekaran 1, Ricardo A Franco 2, Edgar T Overton 2, Brendan M McGuire 3, Graham C Towns 1, Jayme E Locke 4, Deirdre L Sawinski 5, Emmy K Bell 1
 
208.Drug-Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study
 

Int J Environ Res Public Health. 2021 Jul 3;18(13):7144.doi: 10.3390/ijerph18137144.

Alessandra Mangia 1, Francesco Scaglione 2, Pierluigi Toniutto 3, Mario Pirisi 4, Nicola Coppola 5, Giovanni Di Perri 6, Gema Alvarez Nieto 7, Stefano Calabrese 7, Candido Hernandez 8, Valentina Perrone 9, Luca Degli Esposti 9, Stefano Fagiuoli 10
 
209.Prospective cohort study of children exposed to hepatitis C virus through a pregnancy screening program
 

Int J Infect Dis. 2021 Sep;110:62-68. doi: 10.1016/j.ijid.2021.07.019. Epub 2021 Jul 14.

Raquel Borges Pinto 1, Ana Regina L Ramos 1, Leidy Tovar Padua 2, Emma Jane Swayze 3, Mary Catherine Cambou 4, Maristela Fiorini 5, Marineide Melo 6, Breno Riegel Santos 6, Ivete Cristina Teixeira Canti 6, Mara Liane Rieck Silveira 6, Maria Inês Gonzalez Solari 7, Juliana Ferraz de Correa 7, Kara Chew 4, Ivana Rosângela Dos Santos Varella 6, Karin Nielsen-Saines 8
 
210.Impact of Chronic Hepatitis C virus co-infection on outcomes of infective endocarditis in people who inject drugs
 

Diagn Microbiol Infect Dis. 2021 Oct;101(2):115453. doi: 10.1016/j.diagmicrobio.2021.115453.Epub 2021 Jun 12.

Chloe Tom 1, Glen Huang 2, Alexander J Kovalic 3, Kyle A Davis 4, James E Peacock 5
 
211.Hepatitis C in healthcare personnel: follow-up analysis of treatments with direct-acting antiviral agents
 

J Occup Med Toxicol. 2021 Aug 24;16(1):34. doi: 10.1186/s12995-021-00320-4.

Claudia Westermann 1, Dana Wendeler 2, Albert Nienhaus 3 2
 
212.Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort
 

Int J Drug Policy. 2021 Oct;96:103422.doi: 10.1016/j.drugpo.2021.103422. Epub 2021 Aug 21.

Joanne M Carson 1, Behzad Hajarizadeh 2, Josh Hanson 3, James O'Beirne 4, David Iser 5, Phillip Read 6, Anne Balcomb 7, Jane Davies 8, Joseph S Doyle 9, Jasmine Yee 2, Marianne Martinello 10, Philippa Marks 2, Gregory J Dore 11, Gail V Matthews 11, REACH-C Study Group
 
213.Use of telehealth to increase treatment access for prisoners with chronic hepatitis C
 

Intern Med J. 2021 Aug;51(8):1344-1347. doi: 10.1111/imj.15451.

Abir Halder 1, Vicky Guizhi Li 1, Marilyn Sebastian 1, Saroja Nazareth 1, Rhoda Tuma 1, Wendy Cheng 1, Adam Doyle 1
 
214.A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaign
 

J Viral Hepat. 2021 Nov;28(11):1624-1634.doi: 10.1111/jvh.13596. Epub 2021 Aug 28.

Anna Y Palmer 1, Kico Chan 1, Judy Gold 1 2, Chloe Layton 1, Imogen Elsum 1, Margaret Hellard 1 2 3 4 5, Mark Stoove 1 2, Joseph S Doyle 1 3, Alisa Pedrana 1 2, Nick Scott 1 2, on the EC Partnership
 
215.Sofosbuvir-Velpatasvir (Epclusa)-Associated Photosensitivity in a Hepatitis C Patient: Case Report and Review of Photosensitivity to Hepatitis C Antiviral Agents
 

Cureus. 2021 Jul 19;13(7):e16496. doi: 10.7759/cureus.16496.eCollection 2021 Jul.

Stephen E Glombicki 1, Philip R Cohen 2
 
216.Global cascade of care for chronic hepatitis C virus infection: A systematic review and meta-analysis
 

J Viral Hepat. 2021 Oct;28(10):1340-1354. doi: 10.1111/jvh.13574. Epub 2021 Jul 31.

Mohammad T Yousafzai 1, Sahar Bajis 1, Maryam Alavi 1, Jason Grebely 1, Gregory J Dore 1, Behzad Hajarizadeh 1
 
217.Adherence to clinical follow-up recommendations for liver function tests: A cross-sectional study of patients with HCV and their associated risk behaviors
 

Prev Med Rep. 2021 Jul 6;23:101482. doi: 10.1016/j.pmedr.2021.101482. eCollection 2021 Sep.

Allison Dormanesh 1, Judy Huei-Yu Wang 2, Ranit Mishori 3, Paula Cupertino 4, Joshua Longcoy 2, Seble Kassaye 5, Linda Kaljee 6, Coleman Smith 7, Christopher A Loffredo 2
 
218.The Impact of Treatment Delay on Hepatitis C Liver Transplant Outcomes
 

J Pharm Pract. 2021 Jul 21;8971900211034261. doi: 10.1177/08971900211034261.Online ahead of print.

Ian A Booth 1, Jacqueline E Clark 1, John C LaMattina 2, Rolf N Barth 2, Abdolreza Haririan 3, Bharath R Ravichandran 1
 
219.Practice Patterns of Family Physicians With and Without Addiction Medicine Board Certification
 

J Am Board Fam Med. Jul-Aug 2021;34(4):814-819. doi: 10.3122/jabfm.2021.04.200456.

Sebastian T Tong 1, Zachary J Morgan 2, Andrew W Bazemore 2, Aimee R Eden 2, Ruchi M Fitzgerald 2, Lars E Peterson 2
 
220.Sofosbuvir/Velpatasvir For The Treatment Of Hepatitis C In Pediatric Patients
 

Expert Rev Gastroenterol Hepatol. 2021 Oct;15(10):1097-1105.doi: 10.1080/17474124.2021.1963231. Epub 2021 Aug 19.

Chiara Rubino 1, Sandra Trapani 2, Giuseppe Indolfi 1 3
 
221.High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study
 

Open Forum Infect Dis. 2021 Jun 9;8(7):ofab267. doi: 10.1093/ofid/ofab267. eCollection 2021 Jul.

Barnaby Flower 1 2, Leanne McCabe 3, Chau Le Ngoc 1, Hung Le Manh 4, Phuong Le Thanh 4, Thuan Dang Trong 4, Thu Vo Thi 1, Hang Vu Thi Kim 1, Thanh Nguyen Tat 1, Dao Phan Thi Hong 1, An Nguyen Thi Chau 1, Tan Dinh Thi 1, Nga Tran Thi Tuyet 1, Joel Tarning 5, Cherry Kingsley 2, Evelyne Kestelyn 1, Sarah L Pett 3, Guy Thwaites 1, Vinh Chau Nguyen Van 4, David Smith 6, Eleanor Barnes 6, M Azim Ansari 6, Hugo Turner 7, Motiur Rahman 1, Ann Sarah Walker 2, Jeremy Day 1, Graham S Cooke 2
 
222.Mechanisms of HCV resistance to broadly neutralizing antibodies
 

Curr Opin Virol. 2021 Oct;50:23-29. doi: 10.1016/j.coviro.2021.07.003.Epub 2021 Jul 28.

Nicole Frumento 1, Andrew I Flyak 2, Justin R Bailey 3
 
223.Hepatitis C virus care cascade in persons experiencing homelessness in the United States in the era of direct-acting antiviral agents: A scoping review
 

J Viral Hepat. 2021 Nov;28(11):1506-1514. doi: 10.1111/jvh.13583. Epub 2021 Aug 11.

Aubrey Del Rosario 1, Jonathan D Eldredge 1, Sara Doorley 1, Shiraz I Mishra 1, Denece Kesler 1, Kimberly Page 1
 
224.Non-invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)-associated liver disease and sustained virologic response (SVR): 3 years follow-up of a prospective longitudinal study
 

J Viral Hepat. 2021 Nov;28(11):1604-1613. doi: 10.1111/jvh.13587. Epub 2021 Oct 1.

Viola Knop 1, Daniel Hoppe 1 2, Johannes Vermehren 1, Sven Troetschler 1 3, Eva Herrmann 4, Annika Vermehren 1, Mireen Friedrich-Rust 1, Christoph Sarrazin 1 5, Jonel Trebicka 1, Stefan Zeuzem 1, Martin-Walter Welker 1
 
225.Identification of Genetically Related HCV Infections Among Self-Described Injecting Partnerships
 

Clin Infect Dis. 2021 Aug 27;ciab596. doi: 10.1093/cid/ciab596. Online ahead of print.

Damien C Tully 1 2, Judith A Hahn 3, David J Bean 4, Jennifer L Evans 5, Meghan D Morris 5, Kimberly Page 6, Todd M Allen 4
 
226.Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials
 

J Viral Hepat. 2021 Nov;28(11):1635-1642. doi: 10.1111/jvh.13600. Epub 2021 Sep 8.

Edward Gane 1, Victor de Ledinghen 2 3, Douglas E Dylla 4, Giuliano Rizzardini 5, Mitchell L Shiffman 6, Stephen T Barclay 7, Jose Luis Calleja 8, Zhenyi Xue 4, Margaret Burroughs 4, Julio A Gutierrez 9
 
227.Modeling Hepatitis C Elimination Among People Who Inject Drugs in New Hampshire
 

JAMA Netw Open. 2021 Aug 2;4(8):e2119092. doi: 10.1001/jamanetworkopen.2021.19092.

Andrew Blake 1, James E Smith 2
 
228.Hepatitis C Virus Vaccine Research: Time to Put Up or Shut Up
 

Viruses. 2021 Aug 12;13(8):1596. doi: 10.3390/v13081596.

Alex S Hartlage 1 2, Amit Kapoor 1 3
 
229.Podcasts for the Delivery of Medical Education and Remote Learning
 

J Med Internet Res. 2021 Aug 27;23(8):e29168. doi: 10.2196/29168.

Julliana Newman 1, Andrew Liew 2, Jon Bowles 3, Kelly Soady 4, Steven Inglis 2
 
230.Is Hodgkin Lymphoma Associated with Hepatitis B and C Viruses? A Systematic Review and Meta-analysis
 

Cancer Epidemiol Biomarkers Prev. 2021 Sep 20.doi: 10.1158/1055-9965.EPI-21-0548. Online ahead of print.

Callum J R Mullen # 1, Karena D Volesky # 2, Zoë R Greenwald 3, Mariam El-Zein 2, Eduardo L Franco 2
 
231.High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence
 

Am J Gastroenterol. 2021 Sep 1;116(9):1896-1904. doi: 10.14309/ajg.0000000000001332.

Philippe J Zamor 1, Ashley Brown 2, Douglas E Dylla 3, John F Dillon 4, Anne F Luetkemeyer 5, Jordan J Feld 6, David Mutimer 7, Reem Ghalib 8, Eric Crown 3, Sandra S Lovell 3, Yiran Hu 3, Christophe Moreno 9, David R Nelson 10, Massimo Colombo 11, Georgios Papatheodoridis 12, Juergen K Rockstroh 13, Richard Skoien 14, Eric Lawitz 15, Ira M Jacobson 16
 
232.Strategies To Maximize Study Retention And Limit Attrition Bias In A Prospective Cohort Study Of Men Reporting A History Of Injecting Drug Use Released From Prison: The Prison And Transition Health Study
 

Ashleigh Cara Stewart 1 2, Reece Cossar 3 4, Shelley Walker 3, Anna Lee Wilkinson 3 5, Brendan Quinn 3 5, Paul Dietze 3 5 6, Rebecca Winter 3 7, Amy Kirwan 3, Michael Curtis 3 5 8, James R P Ogloff 4, Stuart Kinner 5 9 10 11 12, Campbell Aitken 3 5, Tony Butler 13, Emma Woods 3, Mark Stoové 3 5
 
233.Machine-learning-based predictions of direct-acting antiviral therapy duration for patients with hepatitis C
 

Int J Med Inform. 2021 Oct;154:104562. doi: 10.1016/j.ijmedinf.2021.104562. Epub 2021 Aug 26.

Theodore C Feldman 1, Jules L Dienstag 2, Kenneth D Mandl 3, Yi-Ju Tseng 4
 
234.Optimal Timing of Administration of Direct-acting Antivirals for Patients With Hepatitis C-associated Hepatocellular Carcinoma Undergoing Liver Transplantation
 

Ann Surg. 2021 Oct 1;274(4):613-620. doi: 10.1097/SLA.0000000000005070.

Michael K Turgeon 1, Shimul A Shah 2, Aaron M Delman 2, Benjamin V Tran 3, Vatche G Agopian 3, Joel P Wedd 1, Joseph F Magliocca 1, Ahyoung Kim 4, Andrew Cameron 4, Ali Olyaei 5, Susan L Orloff 5, Matthew P Anderson 6, Chandrashekhar A Kubal 6, Robert M Cannon 7, Jayme E Locke 7, Mary A Simpson 8, Mohamed E Akoad 8, Chelsey P Wongjirad 9, Juliet Emamaullee 9, Amika Moro 10, Federico Aucejo 10, Cyrus A Feizpour 11, Parsia A Vagefi 11, Mindie H Nguyen 12, Carlos O Esquivel 12, Kiran Dhanireddy 13, Vijay Subramanian 13, Alejandro Chavarriaga 14, Marwan M Kazimi 14, Maia S Anderson 15, Christopher J Sonnenday 15, Steven C Kim 16, David P Foley 16, Marwan Abdouljoud 17, Reena J Salgia 17, Dimitrios Moris 18, Debra L Sudan 18, Swaytha R Ganesh 19, Abhinav Humar 19, Majella Doyle 20, William C Chapman 20, Shishir K Maithel 1
 
235.Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications
 

PLoS One. 2021 Sep 16;16(9):e0257369. doi: 10.1371/journal.pone.0257369. eCollection 2021.

Jisoo A Kwon 1, Gregory J Dore 1, Behzad Hajarizadeh 1, Maryam Alavi 1, Heather Valerio 1, Jason Grebely 1, Rebecca Guy 1, Richard T Gray 1
 
236.Adaptive Challenges and Family Support: Patient Self-Management during Treatment for Chronic Hepatitis C
 

Nurs Sci Q. 2021 Oct;34(4):405-412. doi: 10.1177/08943184211031602.

Donald E Bailey Jr 1, Andrew J Muir 2, Michael P Cary Jr 1, Natalie Ammarell 3, Sarah Seaver 4, Emily Scirica 1, Mitch Mah'moud 5, Ruth A Anderson 6
 
237.Non-adherence to LDV/SOF did not predict SVR in a randomized controlled trial of HIV/HCV coinfected persons who use drugs
 

Infect Dis. 2021 Sep 20;jiab477. doi: 10.1093/infdis/jiab477. 

Kathleen M Ward 1, Oluwaseun Falade-Nwulia 1, Juhi Moon 1, Catherine G Sutcliffe 2, Sherilyn Brinkley 1, Taryn Haselhuhn 1, Stephanie Katz 1, Kayla Herne 1, Lilian Arteaga 1, Shruti H Mehta 2, Carl Latkin 3, Robert K Brooner 4, Mark S Sulkowski 1
 
238.Impact of COVID-19-related public health measures on HCV testing in British Columbia, Canada: An interrupted time series analysis
 

Liver Int. 2021 Sep 30. doi: 10.1111/liv.15074. Online ahead of print.

Mawuena Binka 1, Sofia Bartlett 1 2, Héctor A Velásquez García 1, Maryam Darvishian 3, Dahn Jeong 1 4, Prince Adu 1 4, Maria Alvarez 1, Stanley Wong 1, Amanda Yu 1, Hasina Samji 1 5, Mel Krajden 1 2, Jason Wong 1 4, Naveed Z Janjua 1 4
 
239.Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation
 

Liver Int. 2021 Sep 28. doi: 10.1111/liv.15070. Online ahead of print.

Andrea Marcellusi 1 2, Francesco Saverio Mennini 1 2, Murad Ruf 3, Claudio Galli 4, Alessio Aghemo 5 6, Maurizia R Brunetto 7 8, Sergio Babudieri 9, Antonio Craxi 10, Massimo Andreoni 11 12, Loreta A Kondili 13
 
240.Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: A multicentre prospective study
 

J Viral Hepat. 2021 Sep 28. doi: 10.1111/jvh.13617. Online ahead of print.

Valerio Rosato 1, Antonio Ascione 2, Riccardo Nevola 3, Anna Ludovica Fracanzani 4, Guido Piai 5, Vincenzo Messina 6, Ernesto Claar 1, Carmine Coppola 7, Luca Fontanella 2, Rosa Lombardi 4, Laura Staiano 7, Giovanna Valente 5, Maria Chiara Fascione 3, Chiara Giorgione 3, Annalisa Mazzocca 3, Raffaele Galiero 3, Pasquale Perillo 1, Aldo Marrone 3, Ferdinando Carlo Sasso 3, Luigi Elio Adinolfi 3, Luca Rinaldi 3
 
241.Effects of direct-acting antiviral treatment on reducing mortality among Medicare beneficiaries with HIV and HCV coinfection
 

AIDS Care. 2021 Sep 28;1-8. doi: 10.1080/09540121.2021.1981221. Online ahead of print.

Xin Yin 1, Lan Kong 1, Ping Du 2, Jeah Jung 3
 
242.Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the EGG18 study
 

Dig Liver Dis. 2021 Sep 27;S1590-8658(21)00776-3. doi: 10.1016/j.dld.2021.09.007.Online ahead of print.

Vincenza Calvaruso 1, Salvatore Petta 2, Donatella Ferraro 3, Claudia La Mantia 2, Gerlando Gibilaro 2, Giada Reina 2, Velia Chiara Di Maio 4, Anna Licata 5, Francesca Ceccherini-Silberstein 4, Vito Di Marco 2, Antonio Craxì 2
 
243.Cancer in People with and without Hepatitis C Virus Infection: Comparison of Risk Before and After Introduction of Direct-Acting Antivirals
 

Cancer Epidemiol Biomarkers Prev. 2021 Sep 28. doi: 10.1158/1055-9965.EPI-21-0742.Online ahead of print.

Jennifer O Lam 1, Leo B Hurley 2, Jennifer B Lai 3, Varun Saxena 4 5, Suk Seo 6 7, Scott Chamberland 8, Charles P Quesenberry Jr 2, Jamila H Champsi 4, Joanna Ready 9, Elizabeth Y Chiao 10 11 12, Julia L Marcus # 13, Michael J Silverberg # 2
 
244.Impact of COVID-19 on Prescribing Trends of Direct-Acting Antivirals for the Treatment of Hepatitis C in Ontario, Canada
 

Am J Gastroenterol. 2021 Aug 1;116(8):1738-1740.doi: 10.14309/ajg.0000000000001287.

Natalia Konstantelos 1 2, Ahmad Shakeri 1, Daniel McCormack 3, Jordan J Feld 4 5, Tara Gomes 2 3 6, Mina Tadrous 1 2 3
 
245.How can general practitioners support people who inject drugs to engage with direct-acting antiviral treatment for hepatitis C? A qualitative study
 

Aust J Gen Pract. 2021 Oct;50(10):716-721. doi: 10.31128/AJGP-03-21-5899.

Emma Heard 1, Andrew Smirnov 2, Luciana Massi 3, Linda A Selvey 4
 
246.HCV-related lymphoproliferative disorders in the direct-acting antivirals era: from mixed cryoglobulinemia to B-cell lymphoma
 

J Hepatol. 2021 Sep 29;S0168-8278(21)02084-5. doi: 10.1016/j.jhep.2021.09.023.Online ahead of print.

Patrice Cacoub 1, Cloé Comarmond 2, Matheus Vieira 3, Paul Régnier 3, David Saadoun 3
 
247.Changes in clinical scenarios, management, and perspectives of patients with chronic hepatitis C after viral clearance by direct-acting antivirals
 

Expert Rev Gastroenterol Hepatol. 2021 Jun;15(6):643-656.doi: 10.1080/17474124.2021.1877136. Epub 2021 Feb 15.

Riccardo Nevola 1, Luca Rinaldi 1, Letizia Zeni 1, Ciro Romano 1, Aldo Marrone 1, Raffaele Galiero 1, Pia Clara Pafundi 1, Carlo Acierno 1, Erica Vetrano 1, Luigi Elio Adinolfi 1
 
248.Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs
 

J Hepatol. 2021 Oct 8;S0168-8278(21)02103-6. doi: 10.1016/j.jhep.2021.09.038.Online ahead of print.

Alan Yeung 1, Norah E Palmateer 2, John F Dillon 3, Scott A McDonald 2, Shanley Smith 2, Stephen Barclay 4, Peter C Hayes 5, Rory N Gunson 6, Kate Templeton 7, David J Goldberg 8, Matthew Hickman 9, Sharon J Hutchinson 2
 
249.Turning the tide on hepatitis C-related liver transplantation: the return on investment in hepatitis C treatment in Australia and New Zealand
 

Liver Transpl. 2021 Oct 8. doi: 10.1002/lt.26329. Online ahead of print.

Jess Howell 1 2 3 4, Avik Majumdar 5 6, Michael Fink 7 8, Mandy Byrne 7, Geoff McCaughan 5 6, Simone I Strasser 5 6, Michael Crawford 5 6, Peter Hodgkinson 9, Katherine A Stuart 9, Caroline Tallis 9, John Chen 10, Alan Wigg 10, Robert Jones 7 8, Bryon Jaques 11, Gary Jeffrey 11 12, Leon Adams 11 12, Michael C Wallace 11 12, Stephen Munn 13, Ed Gane 13 14, Alex Thompson 1 2, Paul Gow 1 7
 
250.Evaluating the Effectiveness of the AIDS Education and Training Center (AETC) National Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Curriculum
 

J Med Educ Curric Dev. 2021 Sep 30;8:23821205211041178. doi: 10.1177/23821205211041178.eCollection Jan-Dec 2021.

Waridibo E Allison 1, Aro N Choi 1, Keito Kawasaki 1, Trisha V Melhado 1
 
251.BMS-986263 in Patients with Advanced Hepatic Fibrosis: 36-Week Results from a Randomized, Placebo-Controlled Phase 2 Trial
 

Hepatology. 2021 Oct 4. doi: 10.1002/hep.32181. Online ahead of print.

Eric J Lawitz 1, Diane E Shevell 2, Giridhar S Tirucherai 2, Shuyan Du 2, Warner Chen 2, Uma Kavita 2, Angie Coste 1, Fred Poordad 1, Morten Karsdal 3, Mette Nielsen 3, Zachary Goodman 4, Edgar D Charles 2
 
252.Adherence to Hepatitis C Therapy in a Shelter-Based Education and Treatment Model Among Persons Experiencing Homelessness
 

Open Forum Infect Dis. 2021 Sep 25;8(10):ofab488. doi: 10.1093/ofid/ofab488.eCollection 2021 Oct.

Jesse Powell 1, Margaret Ricco 1, Jessica Naugle 2, Catherine Magee 3, Hayat Hassan 1, Carmen Masson 4, Grace Braimoh 1, Barry Zevin 2, Mandana Khalili 3 5
 
253.Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure
 

Nat Commun. 2021 Oct 20;12(1):6105. doi: 10.1038/s41467-021-25649-6.

David A Smith 1, Carlota Fernandez-Antunez 2, Andrea Magri 1, Rory Bowden 3, Nimisha Chaturvedi 4, Jacques Fellay 4 5 6, John McLauchlan 7, Graham R Foster 8, William L Irving 9, STOP-HCV Consortium; Peter Simmonds 1, Vincent Pedergnana 10, Santseharay Ramirez 2, Jens Bukh 2, Eleanor Barnes 1, M Azim Ansari 11 12
 
254.Hepatitis C core antigen test as an alternative for diagnosing HCV infection: mathematical model and cost-effectiveness analysis
 

PeerJ. 2021 Sep 10;9:e11895. doi: 10.7717/peerj.11895. eCollection 2021.

Maryam Sadeghimehr 1, Barbara Bertisch 1 2, Francesco Negro 3, Maia Butsashvili 4, Sonjelle Shilton 5, Irina Tskhomelidze 6, Maia Tsereteli 7, Olivia Keiser 1, Janne Estill 1 8
 
255.Experiences and Perspectives From Women Taking Investigational Therapy for Hepatitis C Virus During Pregnancy
 

Subst Abuse. 2021 Sep 28;15:11782218211046261. doi: 10.1177/11782218211046261.eCollection 2021.

Yasaswi Kislovskiy 1 2, Catherine Chappell 2 3, Emily Flaherty 4, Megan E Hamm 5, Flor de Abril Cameron 5, Elizabeth E Krans 2 3, Judy C Chang 2 3
 
256.Incidence of liver and non-liver-related outcomes in patients with HCV-cirrhosis after SVR
 

J Hepatol. 2021 Sep 27;S0168-8278(21)02043-2. doi: 10.1016/j.jhep.2021.09.013.Online ahead of print.

Roberta D'Ambrosio 1, Elisabetta Degasperi 2, Maria Paola Anolli 2, Ilaria Fanetti 2, Marta Borghi 2, Roberta Soffredini 2, Massimo Iavarone 2, Giulia Tosetti 2, Riccardo Perbellini 2, Angelo Sangiovanni 2, Vana Sypsa 3, Pietro Lampertico 4
 
257.Clinical and Financial Implications of 2 Treatment Strategies for Donor-derived Hepatitis C Infections
 

Transplant Direct. 2021 Sep 7;7(10):e762. doi: 10.1097/TXD.0000000000001222.eCollection 2021 Oct.

Zoe A Stewart 1, Jeffrey Stern 1, Nicole M Ali 1, Harmit S Kalia 1, Karen Khalil 1, Srijana Jonchhe 1, Elaina P Weldon 1, Rebecca A Dieter 1, Tyler C Lewis 1, Nur Funches 1, Sudara Crosby 1, Monique Seow 1, Jonathan C Berger 1, Nabil N Dagher 1, Bruce E Gelb 1, Anthony C Watkins 1, Nader Moazami 1, Deane E Smith 1, Zachary N Kon 2, Stephanie H Chang 1, Alex Reyentovich 1, Luis F Angel 1, Robert A Montgomery 1, Bonnie E Lonze 1
 
258.Kidney Transplantation From Hepatitis C Viremic Deceased Donors to Aviremic Recipients in a Real-world Setting
 

Transplant Direct. 2021 Sep 7;7(10):e761. doi: 10.1097/TXD.0000000000001217.eCollection 2021 Oct.

Beatrice P Concepcion 1, Laura A Binari 1, Heidi Schaefer 1, Scott Rega 2, Irene Feurer 2, Saed Shawar 1, Ruchi Naik 3, Laura Hickman 4, Jasmine Walker 4, Meghan Kapp 5, Kelly A Birdwell 1, Anthony Langone 1, J Harold Helderman 1, Bonnie Ann Sarrell 1